1

people have died from curable diseases

since this page started loading...

💀

The Least Bad Idea in the World Prize: An Implementation Market for Governance Reform

A Standing Prize for the First Mechanism That Can Verifiably Reallocate Resources from Low-Value to High-Value Uses While Surviving Contact with Selfish Humans

One weird trick: score governance reform on 32 metrics, fund whatever wins, replace the winner when something better appears. By construction, the machine is at least as good as anything it finds. Compatible with selfish humans.

Author

Affiliation

Mike P. Sinn

Institute for Accelerated Medicine

Abstract

Current governance mechanisms allocate trillions of dollars based on lobbying intensity, institutional inertia, and political convenience rather than verified net societal value. This paper proposes a standing implementation prize that treats governance reform as an engineering competition rather than a philosophy seminar. The prize scores proposals on a published state vector of 32 variables (cost-effectiveness, welfare impact, political feasibility, capture resistance, and completeness), releases treasury funds only on 2 terminal welfare metrics (median healthy life years and median real income), and awards not cash but adoption capital, political support, distribution, and operating rights. Admissibility requires positive net welfare for every affected class of beings, zero rights violations, complete coverage of the Minimum Acceptable Governance (a required set of governance functions), binding legal force, greed-monotonicity, and automatic reinvestment into missing modules. The ranking rule maximizes risk-adjusted net societal value recovery per dollar of adoption cost, weighted by evidence quality and implementability. The mechanism is compatible with public choice theory: no actor is asked to become less selfish; stronger self-interest makes the system stronger. If the current leading candidate (the Earth Optimization Plan) is optimal, the prize causes its implementation. If a strict improvement exists, the prize discovers and funds that instead. Either outcome dominates the status quo of endless argument with no implementation market.

Keywords

mechanism-design, prize-design, public-choice, governance-reform, implementation-markets, cost-effectiveness, DALY, net-societal-value, resource-allocation, welfare-optimization, incentive-compatibility

Introduction

If this plan is the least bad idea available, the prize causes its implementation. If it is not, the prize finds whatever is better and causes that instead. The point is not to marry a blueprint. The point is to stop subsidizing death, disease, waste, and suffering. We are not sure why your civilization does not already have a machine like this.

To be clear about what is strange here: every constitution on your planet already says the goal of government is to maximize the general welfare. Your species has been on this rock for millions of years. You have had written law for thousands of them. And in all that time, nobody built a machine that measures whether the general welfare is actually being maximized, scores proposals on whether they improve it, and funds whichever one wins. Instead, the primary activity of your governments is funneling wealth to interest groups, terrorizing immigrants, and bombing people of different colors, and the secondary activity is writing eloquent constitutions explaining why they would never do that. The prize is an absurd workaround. It should not be necessary to attach financial incentives to the goal of not killing people in order to get anyone to pay attention to it for more than five seconds. And yet here we are, designing an elaborate mechanism to remind your species of the thing it already wrote down and then immediately ignored. We find this very puzzling.

The cost of the current approach is not abstract. 150 thousand deaths/day people die of treatable disease every day. 102 million (95% CI: 36.9 million-214 million) have already died waiting for drugs that were proven to work but stuck in regulatory queues. The annual economic burden of treatable disease runs $400T (95% CI: $240T-$587T). The total opportunity cost of political dysfunction (the gap between what governance delivers and what it could deliver) is $101T (95% CI: $83.3T-$191T) per year. Those are not projections. They are the running tab for not having a mechanism that selects and implements better ideas.

We noticed that policy design on Earth works like a philosophy seminar: interesting discussions, no binding output. An engineering competition would at least produce prototypes.

Create a standing prize for the first person, team, or institution that can cause the implementation of every required function in the Earth Optimization Plan from the companion papers^{46,72,137–147}, or a strict module-by-module improvement on it, while delivering a lower verified cost per DALY, lower suffering per dollar, and better net outcomes for living beings.

Most prizes on Earth produce a trophy, a speech, and approximately zero change in how resources are allocated. This one is designed to produce a market for verified implementation.

The prize is not “for the Earth Optimization Plan” in the narrow sense. The Earth Optimization Plan is the current default reference package. If another package beats it on the published scorecard and terminal welfare metrics, that rival should win instead. The prize is for causing the best complete implementation, not for loyalty to any specific blueprint.

ImportantDisqualification Rule

If your proposal requires politicians, bureaucrats, investors, regulators, voters, or interest groups to become less selfish than they currently are, you have described a pleasant world rather than a mechanism for reaching it. We have been observing your species since 1945 and have not yet seen selfishness decline on request.

How to read this paper. It does three things: defines what “better” means with a published scorecard, describes the current best candidate and how it achieves its numbers, and explains why a prize is the right selection mechanism. If you want the mechanism before the math, skip to How the Earth Optimization Plan Achieves Its Numbers.

Why Current Systems Fail

The political economy of public goods provision is governed by what Olson¹⁴⁸ called the logic of collective action. Concentrated interests (defense contractors, entrenched pharmaceutical monopolies, legacy energy conglomerates) face high per-capita stakes in policy outcomes, so they easily overcome coordination costs to fund sustained lobbying. Diffuse beneficiaries (the general public dying of untreated diseases, bearing the cost of regulatory delay, or subsidizing low-return military spending) have tiny individual stakes in any single policy fight and cannot coordinate a proportional response.

This keeps happening even though the public has far more money. Global household wealth totals $454T, compared to $5T held by concentrated opposition sectors. The public has the money. It does not have the coordination mechanism. Politicians know which programs have high benefit-cost ratios and which do not. They fund the low-return programs anyway, because right now the concentrated cost of opposing a lobby exceeds the diffuse benefit of pleasing an uncoordinated public¹³⁸.

The prize exists because no existing system solves this, and the closest alternatives each fail on a specific dimension. Advance Market Commitments¹⁴⁹ pre-commit to buy outcomes at a guaranteed price, which works for well-defined products (vaccines) but not for systemic reform where the “product” is governance change plus health infrastructure plus income growth simultaneously; the prize handles this by scoring complete packages on terminal welfare metrics rather than pre-specifying what to buy. Challenge prizes (XPRIZE model) offer a fixed payout for the first team to hit a technical milestone, but the binary payout creates winner-take-all dynamics and funds nothing after the milestone is hit; this prize uses outcome perpetuity (continuing revenue share) so the incentive persists after the first win. Direct government procurement funds what the procurer thinks will work, which IS the current system, and it IS producing Olsonian capture; the prize exists precisely because the procurer is captured. Prediction markets tell you what will win but do not cause implementation. DAOs suffer the same Olsonian capture: whoever buys the most tokens sets the agenda. A prize with published scoring, adversarial challenges, and automatic replacement is the one structure where capturing it requires beating every challenger on verified metrics simultaneously. That is not capture-proof. But it is capture-expensive, which is probably the least bad available.

The Rule

To win the prize, a proposal must clear six tests:

1. Implementation, not commentary. It must produce actual budget reallocations, legal adoption, institutional deployment, or binding coordination, not just a white paper and a podcast circuit.
2. Complete coverage or strict dominance. It must implement every required function in the Minimum Acceptable Governance, or replace each omitted function with a strictly dominating substitute on outcome, feasibility, and durability.
3. Lower verified cost per DALY. If it saves fewer lives per dollar than the Earth Optimization Plan, it loses. If it reduces DALYs cheaply by dumping suffering onto voiceless creatures, it also loses.
4. Net welfare improvement across affected beings. A qualifying plan must not merely move pain from one ledger to another. Offloading harm onto foreigners, future people, patients without bargaining power, or nonhuman animals is disqualification, not cleverness.
5. Reallocation from low NSV to high NSV. The mechanism must redirect resources from uses with low or negative net societal value into uses with higher verified returns.
6. Greed-monotone public-choice compatibility. Every critical actor must have a selfish reason to cooperate, and stronger self-interest should make the mechanism stronger rather than weaker: investors, politicians, bureaucrats, validators, operators, and ordinary citizens.

The “least bad” language matters. The question is not “what is perfect?” It is: which implementable mechanism beats the alternatives once actual humans touch it?

Better Needs Units

Right now “better” is too vague. A real prize needs a published scorecard.

These are the minimum variables the prize should score:

Symbol	What it measures	Why it belongs in the prize	Current anchor from the papers
C_total	Total all-in adoption cost	Political feasibility is a cost question, not a vibes question	Treaty path: $1B; global upper-bound framing from Price of Political Change145: ~$200B
P_success	Probability of binding adoption and sustained implementation	Expected value matters more than conditional fantasy	Conservative central estimate in the Earth Optimization Plan: 1% (95% CI: 0.1%-10%)
T_first	Time to first binding implementation	Delay kills; speed is part of the prize	Right-to-Trial act implies concrete clocks: 180 days, 1 year, 18 months
R_shift	Annual dollars redirected from lower NSV uses to higher NSV uses	The point is resource reallocation, not rhetorical victory	First concrete benchmark: $27.2B/year
NSV_gain	Annual net societal value recovered	Prize should measure recovered value, not just gross spending	Global ceiling: $101T (95% CI: $83.3T-$191T)/year; U.S. waste map: $4.9T (95% CI: $3.62T-$6.5T)/year
CE_conditional	Cost per DALY if adopted	Measures the physics/economics of the policy itself	Treaty path benchmark: $0.00177 (95% CI: $0.000715-$0.00412)/DALY
CE_expected	Risk-adjusted cost per DALY = C_total / (P_success * DALY_net)	Measures the politics plus the policy	Earth Optimization Plan benchmark: $0.177 (95% CI: $0.029-$3.2)/DALY
DALY_net	Net DALYs averted	Core welfare output from the health papers	Earth Optimization Plan medical benchmark: 565 billion (95% CI: 361 billion-877 billion) DALYs
H_suffering	Suffering hours averted	DALYs hide suffering intensity; the prize should not	Earth Optimization Plan medical benchmark: 1.93 quadrillion (95% CI: 1.36 quadrillion-2.62 quadrillion) hours
D_avoided	Deaths averted	Humans understand body counts faster than DALYs	Timeline-shift benchmark: 10.7 billion (95% CI: 7.4 billion-16.2 billion) deaths; historical lag burden: 102 million (95% CI: 36.9 million-214 million) deaths
gIncome_med	Change in real after-tax median income growth	Optimocracy140, OPG141, and OBG142 treat this as the core income welfare metric	Must be reported directly from causal evidence; GDP per capita is not a substitute
Y_avg_20	Average income (GDP per capita) at year 20	The current macro path model expresses ceiling context in per-capita output levels, so keep that separate from the median-income metric	Year-20 reference points: Earth $20.5K, Treaty $339K (95% CI: $106K-$1.33M), Wishonia $1.16M (95% CI: $395K-$6.22M)
dHealthy_med	Change in median healthy life years	The second terminal welfare metric in the governance papers	Must be reported explicitly even when evidence comes through indirect measures
Q_budget	Budget evidence quality	Major spending shifts need a confidence score, not a slogan	OBG’s Budget Impact Score (BIS)142
Q_policy	Policy evidence quality	Law/regulation changes need a causal score	OPG’s Policy Impact Score (PIS)141
Q_signal	Medical signal quality	Medical claims need causal screening before trial escalation	dFDA Predictor Impact Score (PIS)147
Q_trial	Trial-priority quality	The prize should know which validated signals deserve scarce experimental slots	Trial Priority Score = PIS x DALYs x Novelty x Feasibility
A_pref	Preference-alignment score	If the mechanism claims democratic legitimacy, measure it	Wishocracy Citizen Alignment Score139
I_actor_min	Minimum utility delta across key actors	If any required actor is net worse off, the mechanism is probably fiction	Earth Optimization Plan anchors: 272% investor upside, 230 (95% CI: 186-284) mechanism BCR, $454T vs $5T coordination asymmetry
R_capture	Capture/manipulation risk	Every serious governance mechanism gets attacked	Optimocracy’s whole point is to collapse many attack surfaces into a few expensive ones140
B_rights	Hard blocking-factor count	A plan that improves averages by violating rights is not a win	OPG explicitly treats freedom/autonomy constraints as blockers141
W_sentient_net	Net welfare across all affected sentient beings	Prevents fake wins that export suffering to weaker populations or animals	Must stay positive for humans, future people, and nonhuman animals on net
W_class_min	Welfare change for the worst-off affected class of living or sentient beings	Aggregate gains are not enough if any major class is sacrificed	Operational rule: humans, future humans, nonhuman animals, and affected living systems must each be non-negative on the best available model
M_complete	Minimum Acceptable Governance completion score	Prevents narrow proposals from winning by solving only one bottleneck	Grand prize requires 100% coverage of the required-function bundle below
L_bind	Binding-force score	A plan is not implemented until it controls law, budgets, institutions, or enforceable contracts	Binding examples in the Earth Optimization Plan: treaty, statute, agency rule, PAC-financed scorecards, auditable contracts
J_cov	Jurisdictional and population coverage	Pilot success is not system implementation	Must scale to enough authority, budget, and population to match or beat baseline R_shift
T_full	Time to full-bundle deployment	Time to first win is not time to complete Earth Optimization Plan implementation	Measured from launch until every required function is live or dominated
D_durable	Durability under hostile turnover	A plan that dies after one election is not implemented	Must survive leadership change, budget challenge, and organized opposition
G_monotone	Minimum marginal effect of actor self-interest on success	The greedier humans are, the better this should work	Must stay positive for investors, politicians, operators, validators, and citizens
k_pairs	Number of pairwise comparisons required per citizen	Citizens should not need to become full-time budget monks	Wishocracy convergence target: roughly 10-30 pairwise comparisons per participant139
k_capacity	Therapeutic throughput vs. current backlog	Throughput claims should be compared to the disease queue	dFDA benchmark: current 443 (95% CI: 324-712) years vs. 36 (95% CI: 11.6-77.1) years with a 12.3x (95% CI: 4.2x-61.4x) capacity increase143
F_reinvest	Fraction of recovered value automatically recycled into remaining missing modules	Early wins must finance completion of the Earth Optimization Plan rather than stopping at a local maximum	IAB/prize-treasury logic implies positive contractual recycling138

That is the minimum scoreboard. Without it, you are comparing essays, which is how governance proposals have been selected so far, and which has produced the results you currently have.

Minimum Acceptable Governance

This prize is not comparing proposals to isolated papers one at a time. The thing to beat is the integrated bundle of required functions implied by the companion papers.

Required function	Default implementation in the Earth Optimization Plan	What a strict improvement must beat
Large initial reallocation wedge	The 1% Treaty137	Must redirect at least as much low-NSV spending to higher-NSV use, or achieve better welfare with less
Medical throughput and evidence generation	Ubiquitous Pragmatic Trial Impact Analysis143 + The Continuous Evidence Generation Protocol147	Must produce faster, cheaper, more reliable treatment discovery and validation
Regulatory-delay removal	The Invisible Graveyard144 + Right to Trial & FDA Upgrade Act + Drug Development Cost Increase Analysis72	Must reduce efficacy lag and development cost at least as well without increasing net harm
Political financing and adoption engine	Incentive Alignment Bonds138	Must make passage and enforcement at least as incentive-compatible for selfish actors
Citizen preference aggregation	Wishocracy139	Must recover public preference intensity at equal or lower cognitive and organizational cost
Waste and opportunity accounting	The Political Dysfunction Tax46 + United States Efficiency Audit146	Must identify low-NSV pools and recoverable value at least as well
Policy recommendation engine	Optimocracy140 + The Optimal Policy Generator141	Must generate better enact/replace/repeal/maintain recommendations under real-world constraints
Budget recommendation engine	The Optimal Budget Generator142	Must allocate public-goods spending better on the terminal welfare metrics
Legal and institutional implementation path	Right to Trial & FDA Upgrade Act + treaty/statutory tools	Must create equal or stronger binding force in law, budget control, or institutional design
Narrative, coalition, and sequencing wrapper	How to End War and Disease	Must coordinate adoption at equal or lower cost and failure risk

That is the Minimum Acceptable Governance. The grand prize is for the first mechanism that covers every row in that table or replaces any row with a strictly better module.

How the Earth Optimization Plan Achieves Its Numbers

The numbers in the thresholds below sound implausible until you see the mechanisms. Here is enough to evaluate whether each benchmark is credible, in the order they deploy.

Terminology matters here. The Earth Optimization Plan is the integrated implementation bundle. The Current Trajectory, Treaty Trajectory, and Wishonia Trajectory are the modeled macro futures that result if humanity stays on the present course, implements the treaty-and-medical core only, or implements the full bundle respectively.

The full loop: military budgets shrink by 1%, the freed $27.2B/year funds pragmatic trials at 82x (95% CI: 50x-94.1x) lower cost per patient, those trials discover treatments years faster, the treatments save lives and generate economic returns, those returns pay investors who funded the political campaign to pass the treaty, and media coverage of cures creates voter demand that makes expansion easier than repeal. Each stage feeds the next. That feedback loop is why the numbers compound rather than stall.

The reallocation source. The 1% Treaty¹⁵⁰ redirects $27.2B/year by coordinating every signatory to cut the same 1% of military spending simultaneously ($2.72T globally). No new taxes. The game theory is stable because proportional reduction preserves relative deterrence. The economic logic is straightforward: military spending beyond deterrence returns roughly 0.7:1 on welfare; medical research returns 100:1+. The treaty moves money from the worst line item to the best one.

The medical bottleneck. Current clinical trials cost $41K (95% CI: $20K-$120K)/patient and exclude 86% of the population, producing a 443 years (95% CI: 324 years-712 years) backlog to clear 6,650 untreated diseases. Pragmatic trials embedded in routine care cost $929 (95% CI: $97-$3K)/patient (the RECOVERY trial found dexamethasone in 3 months for $500 (95% CI: $400-$2.5K)/patient and saved 1 million lives (95% CI: 500 thousand lives-2 million lives)^86,87). At treaty funding through that cheaper infrastructure, the queue drops to 36 years (95% CI: 11.6 years-77.1 years). Meanwhile, 102 million (95% CI: 36.9 million-214 million) people died waiting an average of 8.2 years (95% CI: 4.85 years-11.5 years) for drugs that were already proven to work but stuck in regulatory queues²³. Right to Trial eliminates that lag by allowing conditional access after Phase I safety data.

The political adoption engine. Incentive Alignment Bonds flip the Olsonian equilibrium through three layers: an independent organization scores politicians on net-social-value voting records, PACs support high-scorers and oppose low-scorers, and foundations guarantee post-office careers for champions. Voting for high-NSV programs becomes the career-maximizing choice. Investor returns (272% annually) come from revenue share of treaty-generated funding flows, not from magic; the benefit-cost ratio of the mechanism itself is 230 (95% CI: 186-284)¹³⁸.

The waste map. The Political Dysfunction Tax ($101T (95% CI: $83.3T-$191T)/year) is not a spending figure. It is the gap between actual output and optimal-governance output, aggregating a waste ledger (military overspend, healthcare administration, regulatory burden) and an opportunity ledger (delayed cures, migration barriers, lead poisoning). The US Efficiency Audit itemizes $4.9T (95% CI: $3.62T-$6.5T)/year across ten categories; the three largest are healthcare administration, housing policy failure, and excess military spending^46,146.

The information engine. The information necessary for optimal governance already exists, scattered across thousands of jurisdictions running natural experiments in real time. Optimocracy¹⁴⁰ harvests those results: which policies actually improve median income and health, which ones fail, and by how much. The Optimal Policy Generator¹⁴¹ turns that into concrete enact/replace/repeal recommendations. The Optimal Budget Generator¹⁴² does the same for spending allocations. The same infrastructure that recommends policies also verifies whether the prize’s terminal metrics moved: the Optimitron continuously runs causal inference on incoming jurisdictional data, so it serves as both the recommendation engine and the milestone verification layer. The bottleneck is not knowledge. It is that politicians substitute their donors’ preferences for the public’s, and there has been no mechanism to make that substitution visible or costly.

Preference aggregation. Wishocracy eliminates that bottleneck. It asks citizens to drag a slider between two random budget priorities (“Nuclear modernization vs. clinical trials?”). About 20 comparisons, 5 minutes. Random pairs prevent gaming. Statistical models (Bradley-Terry, PageRank) aggregate millions of pairwise judgments into budget-preference weights without speeches, lobbying, or horse-trading. The result is a published, auditable map of what the public actually wants, at intensities politicians cannot plausibly claim to represent better. When Optimocracy tells you what works and Wishocracy tells you what people want, the politician’s role shrinks from “decide everything” to “execute or be replaced.” Crowds consistently outperform expert panels on preference recovery¹³⁹.

None of these mechanisms require inventing new physics. The Montreal Protocol coordinated proportional reduction across nations and worked. PEPFAR redirected tens of billions of dollars into health and saved millions of lives. The RECOVERY trial proved pragmatic trials deliver at 82x (95% CI: 50x-94.1x) lower cost per patient. The open question is not whether coordinated reallocation, pragmatic trials, or incentive-aligned political financing work individually. It is whether combining them into a single plan, selected and funded via prize, produces better results than deploying them separately or not at all.

The Completeness Rule

The grand prize is not for the cheapest local patch. It is for the first mechanism that closes the whole loop from diagnosis to reallocation to durable implementation.

1. Every required function in the Minimum Acceptable Governance must be implemented directly or replaced by a dominating substitute.
2. A substitute counts as dominating only if it matches or improves cost per DALY, suffering reduction, coverage, durability, and greed-compatibility relative to the module it replaces, and genuinely improves at least one of those dimensions.
3. Partial packages may win early-stage bounties (specification, pilot, adoption), but they do not win the grand prize.
4. If a proposal begins with only part of the bundle live, a fixed share of verified recovered value must be contractually routed into the remaining missing functions until M_complete = 1 or every missing function has a certified dominating substitute.

To put the cost-effectiveness threshold in context:

Intervention	Cost per DALY averted
Malaria bed nets (current gold standard)	$89 (95% CI: $78-$100)
1% Treaty (conditional, if adopted)	$0.00177 (95% CI: $0.000715-$0.00412)
1% Treaty (risk-adjusted, 1% (95% CI: 0.1%-10%) success)	$0.177 (95% CI: $0.029-$3.2)

Any proposal that cannot beat the risk-adjusted treaty benchmark on cost per DALY, or clearly dominate it on other welfare dimensions, does not get scored.

The Admissibility Rule

A proposal should not even enter the final ranking unless all of these are true:

\[ \begin{aligned} W_{sentient,net} &> 0 \\ B_{rights} &= 0 \\ W_{class,min} &\ge 0 \\ M_{complete} &= 1 \\ L_{bind} &> 0 \\ G_{monotone} &> 0 \\ F_{reinvest} &> 0 \\ J_{cov} &\ge J_{baseline} \\ D_{durable} &\ge D_{min} \\ I_{actor,min} &> 0 \\ R_{shift} &> 0 \\ CE_{expected} &\le CE_{baseline,best} \end{aligned} \]

Here \(J_{baseline}\) means enough authority, budget, and population coverage to match or beat the Minimum Acceptable Governance’s implementation footprint, and \(D_{min}\) means at least two election cycles or equivalent treaty/contractual lock-in. Those are the hard blocking rules: no sacrificed class, no missing module, no non-binding pilot, and no mechanism that gets worse when humans act selfishly.

Welfare Accounting Protocol

The welfare guardrails above are not poetry. They need real rules.

Every serious proposal should publish a class-by-class impact table with at least these rows:

• present humans
• future humans
• nonhuman animals directly affected
• nonhuman animals indirectly affected through land use, food systems, or ecological spillovers
• ecosystems whose decline would cause lasting suffering

For each class, the submission should report:

• direct expected welfare change
• lower-bound welfare change under conservative assumptions
• main uncertainty sources
• irreversibility risk
• rights/blocking-factor flags
• proposed mitigation or compensation path if the lower bound is near zero

The operational rule is simple:

1. Use lower bounds, not central estimates, for admissibility. If a class looks positive only on optimistic assumptions, the proposal is not yet admissible.
2. Count uncertainty against the proposal. Unknown but plausible severe harms count as negative until measurement improves.
3. Keep rights as hard constraints. A proposal does not buy its way out of coercion, fraud, or autonomy violations by producing a large aggregate gain elsewhere.
4. Separate welfare from money. Dollar figures help you sense the scale, but they do not substitute for DALYs, suffering, mortality, or class-specific welfare accounting.

That is how W_sentient_net, W_class_min, and B_rights stop being slogans and become real tests.

The Ranking Rule

Among admissible proposals, rank them by something like:

\[ PrizeScore = \frac{P_{success} \times NSV_{gain} \times Q_{evidence}}{C_{total}} \]

Where \(Q_{evidence}\) is a confidence-and-practicality score built from the project’s own scoring tools:

\[ Q_{evidence} = \text{geometric mean}(Q_{budget}, Q_{policy}, Q_{signal}, Q_{trial}, A_{pref}, L_{bind}) \]

Operationally, the ranking should be read in priority order, not as one combined score:

1. Clear admissibility.
2. Maximize expected suffering reduction and DALYs averted per dollar.
3. Then maximize risk-adjusted NSV_gain / C_total among proposals that already tie on the health and welfare numbers.

That ordering matters. It stops a plan that mostly looks good on economic growth from beating a plan that actually reduces more suffering, just because the growth numbers are bigger.

Then use tie-breakers in this order:

1. Lower CE_expected
2. Higher W_class_min and W_sentient_net
3. Shorter T_full and T_first
4. Lower R_capture
5. Higher dHealthy_med and gIncome_med
6. Higher G_monotone and F_reinvest

That gives you a prize that can actually pick a winner instead of just admiring prose.

The Prize Is a Machine, Not a Check

A normal prize gives someone cash after they do something impressive. That is fine for building a better battery. It is useless for governance reform, because the hard part is not inventing the idea. The hard part is forcing implementation through institutions designed to resist it.

So the prize has to award the thing that matters:

• Adoption capital. The leading proposal gets access to the financing infrastructure needed to pass it.
• Distribution. The leading proposal becomes the default object of campaign messaging, coalition building, and ballot-measure campaigns.
• Political support. Politicians who adopt the leading proposal get scored, promoted, and financed through the same incentive system described in the companion papers.
• Operating rights. The winning implementation team gets the prestige, contracts, revenue share, or administrative role attached to actually making the system work.
• Completion covenant. A fixed share of verified recovered value automatically goes to any still-missing baseline functions until the whole bundle is live or every missing function is replaced by a dominating substitute.
• Independent escrow and recertification. Prize capital sits in an auditable treasury with published scoring, challenge windows, and periodic re-ranking so capture cannot freeze a bad winner in place.
• Automatic replacement. If a superior proposal appears later, the prize funding and political support migrate to that one instead.

That last point is the whole trick. The prize does not defend any particular proposal against better ideas. It uses better ideas to unstick worse ones. The obvious objection is that replacement threat creates perverse incentives: if the incumbent knows a better proposal can steal its funding, why not extract value quickly and leave? Because the biggest reward is outcome perpetuity, a continuing revenue share that only flows while you keep producing results. Extracting and leaving forfeits the perpetuity stream. The ongoing incentive dominates the one-time extraction incentive. This is how franchise contracts already work, and competition still beats monopoly on your planet despite every franchisee facing the same replacement risk.

How the treasury gets funded is an operational question, not a constitutional one. Contributions, grants, philanthropic commitment, assurance contracts¹⁵¹, revenue-share instruments, or any combination that clears the escrow rules will work. The prize is the selection and implementation machine. The fundraising mechanism is replaceable plumbing. The maximum cost of achieving any policy change through legal democratic channels is $1B for the United States and roughly $200B globally, with ROI exceeding 400,000:1 for military-to-health reallocation¹⁴⁵. “Political impossibility” is a capital allocation problem, not a physics problem, and the returns make it a very easy one.

Prize Constitution

To make the phrase “causes implementation” mean something, the prize needs a constitution, not just a mission statement.

At minimum, that constitution should define five functions. These are functions, not job titles. Each one is performed by code enforcing published rules. Humans participate through the protocol (asserting metrics, disputing claims, doing pairwise comparisons, building things), but no function requires a human in a governance role.

1. Treasury custody. Capital is held in escrow and may be released only by the published deployment rule. Code enforces the release conditions and no human can override them.
2. Metric assertion and dispute. Anyone can assert that a proposal meets a specific scorecard value, posting evidence and a bond. Anyone can dispute that assertion by posting a counter-bond with contrary evidence. If undisputed for the challenge window, the assertion stands. The scorecard is the committee. Evaluation is measurement, not judgment. The rules are public, the evidence is public, and the formula computes the rank. (The objection that nobody will monitor all these variables answers itself: competing implementers will, because every metric the current leader inflated is an opportunity to displace them. The natural short seller is the next team that wants to win.)
3. Challenge resolution. Automated verification for mathematically checkable metrics; contribution-weighted pairwise evaluation for empirical ones. No standing panel. No appointed judges. (See Challenge and Dispute Resolution for the full process.)
4. Execution. Implementers self-select. They do work (campaign finance, legislative drafting, trial recruitment, software, coalition building), then claim credit through the retroactive impact purchasing mechanism. Contributors evaluate claimants via pairwise comparison. The prize does not appoint an action team. It pays whoever produces verified results.
5. Re-ranking. New metric assertions trigger automatic re-computation of PrizeScore. The machine replaces the current winner when something scores higher. No periodic review board. The protocol watches continuously.

The constitutional rules should be equally blunt:

• No ordinary override. No board, founder, donor, or politician may keep capital on a lower-ranked package just because they prefer it.
• Automatic migration trigger. If the current winner loses admissibility or is strictly beaten on the published rule for a full review cycle, funding and support move automatically.
• Emergency pause is narrow. The only valid pause grounds are fraud, rights violations, or newly discovered severe downside risk, and a pause must trigger immediate public re-review rather than quiet discretion.
• Money must keep moving. If capital sits idle, the machine is broken. Treasury funds go to the best available plan that clears the rules.
• The protocol itself is replaceable. The prize protocol, including the scorecard, the ranking rule, and the challenge process, is a scoreable module. A strictly better selection mechanism replaces the current one under the same replacement rule. “Strictly better” means: plans selected under the new mechanism dominate plans selected under the old one, measured on the same terminal welfare metrics (DALYs, suffering, median income). The terminal metrics are the fixed point. Everything building toward those metrics is improvable plumbing.

That is the missing bridge between “great selection rule” and “a machine that only moves forward.”

Instance Compatibility

The protocol can have many instances sharing one constitution. An instance is compatible if it uses the same scorecard, admissibility rules, automatic migration, and completeness rule. Many organizations may brand and market their own instance; many brand names are fine. Many constitutions are not. The practical test: can two instances look at the same submission and agree on whether it is admissible, how it scores, and whether it beats the current leader? If yes, they are compatible. If no, they are separate prizes that happen to have similar names.

Milestone-Based Release

The constitution should not release all treasury capital at once. A milestone ladder distributes funds as implementation progresses, so only a fraction is at risk at any given time, and each milestone is independently verifiable.

Metric	What it measures	Share of funds	Trigger	Verification
dHealthy_med	Median healthy life years gained	50%	Released proportionally as measured health gains cross pre-published thresholds in at least one jurisdiction	Peer-reviewed quasi-experimental study or RCT with causal attribution
gIncome_med	Median real after-tax income growth	50%	Released proportionally as measured income gains cross pre-published thresholds in at least one jurisdiction	Peer-reviewed quasi-experimental study with causal attribution

The table has two rows because those are the two terminal welfare metrics. Everything the prize exists to produce is either healthy life years or income. If healthy life years went up, trials worked, money moved, and legislation passed. If income rose, governance reform functioned. Paying separately for budget reallocation or trial enrollment is paying for plumbing that may or may not deliver water. Pay for water. The bounty structure below (spec/pilot/adoption) already funds early-stage implementation work; the milestone table governs the main treasury and releases only on proven outcomes. These are complementary: bounties fund implementation, milestones pay for results. Fraud is also harder with terminal metrics, because the Minimum Acceptable Governance already includes the verification infrastructure. The Optimitron¹⁴⁰ measures both terminal metrics through five independent sources (Census Bureau, Federal Reserve, BLS, academic panel studies, and tax data) aggregated by median, plus a sixth methodology-independent stream from decentralized citizen surveys. Corrupting this requires simultaneously bribing five institutions with different governance structures, different funding sources, and different reasons to hate each other, without any of them noticing or telling anyone. Faking budget transfers requires one cooperative auditor. Faking population-level health and income outcomes across five independent measurement systems is the plot of a movie where the criminals lose.

Two objections arise immediately.

First: terminal metrics take years to measure, so who funds the implementation work in between? That is not a bug. It is venture capital. Retroactive impact purchasing lets implementers fund work up front with private capital and get reimbursed after verified outcomes exist. Every serious investment operates on multi-year horizons. The measurement lag is the filter: if you cannot sustain implementation long enough for outcomes to become measurable, you did not implement anything worth paying for.

Second: causal attribution at the macro level is hard. How do you prove that this reform caused the income increase rather than a tech boom or commodity swing? You do not need global proof. The table says “in at least one jurisdiction.” Staggered treaty adoption hands you the natural experiment: signatories vs. non-signatories, difference-in-differences or synthetic control. That is exactly how PEPFAR was evaluated. And the Minimum Acceptable Governance already includes the machine built to run those analyses continuously: the Optimitron¹⁴⁰ applies synthetic control, difference-in-differences, and regression discontinuity across thousands of jurisdictions that already made different policy choices. It does not wait for an academic team to design a study, secure funding, and publish. It processes incoming data from all jurisdictions as it arrives. The attribution lag shrinks from “years for someone to do the study” to “months for the data to update.” And if people in adopting jurisdictions are measurably richer and less dead than people in non-adopting ones, the academic identification debate is a luxury the dead cannot afford.

Challenge and Dispute Resolution

Scoring without a published dispute process is a press release, not a machine. The challenge process needs four features.

Fixed window. Every scored milestone opens a challenge period of fixed duration (e.g. 30 days), published in advance. No score is final until the window closes.

Challenge bond. A challenger posts a bond equal to a fixed percentage of the disputed milestone tranche. If the challenge fails, the challenger forfeits the bond. If it succeeds, the original scorer absorbs a proportional penalty. This filters noise without silencing real objections.

Escalation ladder. First-round challenges are resolved by evidence publication: both sides post their data, and if the metric is mathematically verifiable, automated verification settles it. For empirical metrics, resolution goes to contribution-weighted pairwise evaluation: randomly selected contributors compare the competing evidence packages, weighted by their stake. Each round costs the losing side more, so frivolous escalation is expensive but genuine disputes reach resolution without a standing committee.

Published standard. The challenge rules must state in advance what evidence can change a score, what cannot, and what conditions trigger automatic fund release after the challenge window closes. If those rules are not public before money moves, your first real controversy will turn the prize into a comment section with escrow.

How the Payout Works

The payout should be heavily back-loaded. We have noticed that your species is remarkably good at collecting money for plans and then not building the plans. This is one of your more puzzling traits.

1. Specification bounty. A small amount for producing a complete, auditable, adversarially reviewed mechanism.
2. Pilot bounty. A larger amount for a live pilot that moves real money, changes real behavior, and survives contact with real institutions.
3. Adoption bounty. A much larger amount for statute, treaty, agency rule, ballot measure, or other binding implementation.
4. Outcome perpetuity. The biggest reward is a continuing share of verified recovered value, because one-time prizes create demos while ongoing revenue shares create permanent constituencies.

The current leading candidate uses Incentive Alignment Bonds¹³⁸ as one implementation of this structure. But the prize does not require IABs specifically. It requires that the winning plan include a back-loaded payout with outcome perpetuity. How the plan finances itself is its problem, not the prize’s.

Retroactive Impact Purchasing

The prize can pay for proven results after they happen. Implementers fund work up front using their own capital or outside investment, produce auditable outcomes, and then get paid for outcomes they can prove only after the outcomes exist. In the medical domain, claims would typically be measured in audited DALYs averted, suffering hours avoided, or verified mortality reduction. In governance domains, they would be measured in verified resource reallocation, durable policy adoption, or measured welfare gains under the same admissibility constraints.

This layer remains under the completeness rule rather than replacing it. Retroactive purchasing is a way to pick and fund projects within the winning plan, not a license for narrow local patches to outrank complete packages. The prize first decides which complete implementation plan wins. Only then do decentralized implementers compete to supply the cheapest verified components within that plan.

Retroactive Credit Allocation

Everything above assumes you define winning conditions before money moves: score this, beat that threshold, collect the prize. But there is an alternative. Wait until the thing actually happens, then let the people who funded it decide who deserves credit.

The mechanism has two stages.

Stage one: objective trigger. The treaty gets signed by N countries, or the clinical trial infrastructure goes live, or whatever measurable condition you defined. This is verified the same way as any other prize condition (bonded assertion, dispute window, oracle confirmation). Until the trigger fires, the treasury stays locked. No trigger, automatic refund.

Stage two: pairwise credit allocation. After the trigger fires, every contributor who put money into the pool is shown random pairs of claimants. Each claimant links to evidence of their contribution: public records, legislative histories, commit logs, news coverage, whatever they have. The contributor splits their share of the pool between the two claimants based on the evidence. Not a vote on the whole pot. Their money, their call.

Why pairwise comparison instead of “rank all 10,000 claimants”: because nobody can evaluate 10,000 candidates, but anyone can look at two evidence packages side by side and make a reasonable judgment. Run enough random pairs across enough contributors and the individual allocations converge on a stable credit distribution. This is the same mathematics behind competitive rating systems and preference learning.

Why “their share” instead of “their vote”: because it kills three problems at once.

1. No sybil attacks. Fake accounts have zero funds to allocate. You can only split money you actually deposited. The deposit itself is the identity check.
2. No majority tyranny. Your allocation moves your money, not mine. No coalition can redirect my share against my judgment.
3. It is a market, not an election. Each contributor is a buyer choosing where their dollars go based on evidence. Markets aggregate distributed information better than polls.
4. No kingmaking. The objection that larger contributors have disproportionate influence assumes they can target it. They cannot. Pairs are assigned randomly. A billionaire who wants to steer credit toward a preferred implementer would need that implementer to appear in every random pair, which the randomization prevents. Over thousands of pairs across thousands of contributors, individual bias is statistical noise. This is the same property that makes the mechanism sybil-resistant: the randomization that prevents fake accounts from concentrating influence also prevents real accounts from concentrating it.

The same mechanism resolves metric disputes during plan scoring. When two parties disagree about a metric value, randomly selected contributors evaluate the competing evidence packages via pairwise comparison, weighted by contribution. The deposit-as-identity property means sybil resistance is free for disputes too.

What this does not solve. Recency bias: the person who gave the final speech has flashier evidence than the person who spent three years quietly building the coalition. Strategic sandbagging: if I recognize my competitor in a pair, I allocate zero to them regardless of evidence (mitigated by random assignment and large voter pools, where any one person’s spite is statistical noise, but not eliminated). And the number of comparisons needed scales with the number of claimants; roughly N log N pairs distributed across all voters, which at 10,000 claimants means maybe 20 to 30 comparisons per contributor. Manageable, but not nothing.

One Concrete Run

Abstract mechanism design is harder to trust than a concrete example. So here is what the Earth Optimization Plan would look like if it won.

1. The treasury raises the initial pool through contributions, grants, or philanthropic commitment and escrows it under the no-override rules above.
2. The current bundle is submitted as the default reference package, not as a sacred blueprint: treaty wedge, dFDA^143,147 / continuous evidence generation, regulatory-delay removal, IAB adoption system, Wishocracy preference aggregation, Optimocracy¹⁴⁰ / OPG¹⁴¹ / OBG¹⁴² recommendation engines, and the statutory path.
3. The submitter asserts metric values for each admissibility constraint, posting evidence and a bond. After the challenge window closes without successful dispute, admissibility is confirmed. It clears because it covers every required function, beats the current DALY benchmark, and preserves the public-choice and welfare constraints.
4. Money goes to the first binding path with the best expected payoff: campaign finance, legislative drafting, treaty advocacy, scorecards, and public preference collection.
5. Once one binding path succeeds, budget authority and legal authority start shifting real resources rather than merely improving discussion quality.
6. That first success funds the next missing or underpowered modules automatically through the completion covenant until the whole bundle is live.
7. Implementers then compete inside that winning bundle to supply the cheapest verified pieces, and later challengers can still replace the whole bundle if they genuinely dominate it.

That is the level of concreteness required for “implementation market” to mean more than “good intentions with a spreadsheet.”

Why Public Choice Theory Approves

Public choice theory says governments are not run by philosopher-kings. They are run by humans who care about reelection, career advancement, and reputation. This is not a design flaw in humans. It is a design constraint. The prize works with it.

The prize is compatible with public choice because no one has to become good:

• Entrepreneurs compete for a giant implementation franchise.
• Investors compete for a share of recovered value.
• Politicians compete for campaign support, better scores, reelection odds, and post-office careers.
• Bureaucrats compete for control of a better-funded, higher-status program instead of a shrinking one.
• Researchers and auditors compete for the authority to validate what works.
• Citizens get simpler choices and more visible returns from participation.

Nobody is asked to sacrifice self-interest. Self-interest is pointed in a better direction. More importantly, the design goal is that greed helps: as greed rises, capital supply, monitoring effort, political pressure, and reinvestment should all rise with it rather than collapse.

Why Contributing Is Rational for You Personally

The arithmetic is simple. If the treaty trajectory is even roughly correct, success raises average lifetime income by $14.9M (95% CI: $3.61M-$67.9M) per person. Any action you take that shifts implementation probability by even a tiny amount is worth real money to you personally:

Increase in implementation probability	Personal expected value (Treaty Trajectory floor, $14.9M (95% CI: $3.61M-$67.9M))	Personal expected value (Wishonia Trajectory, $52.1M (95% CI: $15.3M-$316M))
0.01 percentage points	+$1.49K	+$5.21K
0.1 percentage points	+$14.9K	+$52.1K
1 percentage point	+$149K (95% CI: $36.1K-$679K)	+$521K (95% CI: $153K-$3.16M)

Those are not projections about other people’s welfare. They are projections about your income.

If you contribute implementation work (research, software, policy drafting, trial recruitment, coalition building), the retroactive impact purchasing mechanism adds a second channel: the prize can pay you directly for verified outcomes. You fund work up front, produce auditable results, and the prize treasury reimburses you based on measured impact. That is a direct financial return on top of the population-wide gain.

The cost of not acting is not zero. Political dysfunction already costs $12.6K (95% CI: $10.6K-$23.4K) per person per year in unrealized value. The destructive economy (military spending beyond deterrence plus cybercrime) is already 11.5% of GDP. If current growth rates continue, it reaches 25% in 8 years and 50% in 15 years. At 50%, the parasitic economy exceeds the productive one. The incentive structure of a failed state applies globally, and the transition is probably irreversible because the institutions that could reverse it no longer function. The modeled probability of reaching that regime is 10% (95% CI: 2%-29.4%) at year 20. “Do nothing” is not a neutral baseline. It is a bet that these trends reverse without intervention.

So the individual expected value of contributing has four channels:

Channel	What it is	Conservative anchor
Population-wide gain	Your share of per-capita income gain from better resource allocation	$14.9M (95% CI: $3.61M-$67.9M) (Treaty floor) to $52.1M (95% CI: $15.3M-$316M) (Wishonia)
Retroactive rewards	Direct payment from the prize treasury for verified outcomes you helped produce	Proportional to audited DALYs, suffering hours, or welfare gains you can prove
Avoided downside	Reduced personal exposure to compounding dysfunction tax and collapse risk	$12.6K (95% CI: $10.6K-$23.4K)/year ongoing; 10% (95% CI: 2%-29.4%) collapse probability at year 20
Humanitarian impact	DALYs averted, lives saved, and suffering hours prevented per probability point you shift	5.65 billion DALYs (95% CI: 3.61 billion DALYs-8.77 billion DALYs) DALYs / 107 million (95% CI: 74 million-162 million) lives / 19.3 trillion hours (95% CI: 13.6 trillion hours-26.2 trillion hours) suffering hours per percentage point

The break-even probability shift for any given contribution is small because the per-capita stakes are large:

Your unreimbursed contribution	Break-even probability shift (Treaty floor)	Break-even probability shift (Wishonia)
$1K	0.0067%	0.0019%
$10K	0.067%	0.019%
$100K	0.671%	0.192%
$1M	6.71%	1.92%

Those thresholds are biased against contributing because they count only the population-wide income channel and ignore both retroactive rewards and the value of reducing downside exposure. They also survive heavy skepticism. If you think the per-capita gain is 100x smaller than modeled ($149K instead of $14.9M), the break-even for a $1K contribution is still only 0.67%. The math does not require trusting the model. It requires believing the model is not off by more than four orders of magnitude. And the ceiling cost of achieving the policy change is already bounded: $1B for the United States, roughly $200B globally, with ROI exceeding 400,000:1 for military-to-health reallocation¹⁴⁵. “Politically impossible” is a statement about price, not physics, and the price is trivial relative to the returns.

The free-rider problem has a structural answer. The obvious objection is: if success benefits everyone equally, why not wait and let others pay for it? That is the Olsonian collective action failure the paper’s own “Why Current Systems Fail” section identifies as the core problem. The prize answers it at two levels.

At the prize level, retroactive impact purchasing pays contributors for verified outcomes. If you do implementation work, the prize treasury reimburses you based on audited results. Non-contributors have no outcomes to claim. This is a feature of the prize itself, not any specific plan, so it works regardless of which plan wins.

At the plan level, the admissibility rule does the work. Rule 6 requires greed-monotone public-choice compatibility: every critical actor must have a selfish reason to cooperate, and stronger self-interest must make the mechanism stronger. Any plan that fails this test is disqualified before it reaches the scorecard. That means whatever plan wins, it must include private return channels for investors, operators, and participants. The current leading candidate does this through Incentive Alignment Bonds (investors receive returns from treaty revenue share). A different winning plan would use a different mechanism. The prize does not specify how participants get paid. It requires that they do.

Everyone gets the population-wide gain whether they contributed or not, but private return channels (retroactive impact payments, investor returns, operator fees) are reserved for participants. Free-riding is not punished; it is merely less profitable than contributing. Early contributors raise the probability of success, which raises the expected value for later contributors, creating a coordination game that runs on arithmetic rather than altruism.

The deeper answer is that the free-rider objection targets the wrong funding model. Free-riding is a problem for public goods financed by donations, where every donor would prefer someone else to pay. But Rule 6 guarantees that whatever plan wins must include private return channels; plans without them are disqualified. So the prize is not financed by altruism. It is financed by investors buying revenue-share instruments with direct financial returns. Nobody free-rides on buying stocks. The investor’s return is private, contractual, and proportional to their investment. The population-wide gain is a positive externality of the investment, not the investment thesis.

What the Prize Selects if These Papers Are Right

If the papers in this project are broadly correct, a serious prize process will not ignore them. It will rediscover them, combine them, and then fund them because the completeness rule prevents any narrow alternative from winning unless it actually replaces the missing functions.

Paper	What the prize uses it for	Key benchmark to beat	Why that benchmark is not insane
The 1% Treaty137	The first large, legible transfer from low-value military spending to high-value medical discovery.	$27.2B/year redirected; $0.00177 (95% CI: $0.000715-$0.00412)/DALY conditional; 10.7 billion (95% CI: 7.4 billion-16.2 billion) deaths averted	The wedge is just 1% of roughly $2.72T in military spending, and the health upside inherits the pragmatic-trial cost structure rather than legacy Phase III costs.
Ubiquitous Pragmatic Trial Impact Analysis143	The ROI case for why medical evidence generation is one of the best early destinations for redirected capital.	12.3x (95% CI: 4.2x-61.4x) capacity increase; queue clearance from 443 (95% CI: 324-712) years to 36 (95% CI: 11.6-77.1) years; $0.842 (95% CI: $0.242-$1.75)/DALY	The multiplier comes from funding roughly 23.4 million (95% CI: 9.46 million-97 million) patients/year at $929 (95% CI: $97-$3K) per pragmatic-trial patient instead of relying on $41K (95% CI: $20K-$120K) traditional trials.
Incentive Alignment Bonds138	The financing and political-adoption engine that turns “good policy” into an investable asset class.	272% annual investor return; 230 (95% CI: 186-284) mechanism BCR; three-layer structure (scoring, electoral support, post-office careers)	The mechanism rides existing PAC and campaign-finance infrastructure, and the capital base is plausible because diffuse beneficiaries control $454T versus $5T for concentrated opposition sectors.
Wishocracy139	The preference-aggregation layer that tells the system what people actually want, with intensity instead of slogans.	Binding use at >=2% participation; convergence in 10-30 pairwise comparisons per citizen	The benchmark is modest because citizens answer simple pairwise budget tradeoffs rather than mastering an entire policy platform, which keeps cognitive load low enough to scale.
The Political Dysfunction Tax46	The master ledger showing how much value current governance leaves on the floor.	$101T (95% CI: $83.3T-$191T)/year in recoverable value globally	Each component draws from independently measured sources (WHO disease burden, SIPRI military data, OECD healthcare benchmarks); the aggregation is arithmetic, not modeling. The current model sums roughly $34T health delay, $4T underfunded science, $6T lead, and $57T migration losses.
The Invisible Graveyard144	The mortality proof that delay itself is an active killing mechanism, not a neutral inconvenience.	8.2 (95% CI: 4.85-11.5) years average regulatory delay; 102 million (95% CI: 36.9 million-214 million) historical deaths; 7.94 billion DALYs (95% CI: 4.43 billion DALYs-12.1 billion DALYs); $1.19 quadrillion (95% CI: $443T-$2.41 quadrillion) deadweight loss	The delay is directly observed in FDA approval timelines, not estimated from theory. The deaths are calculated from WHO disease burden data for conditions those delayed drugs treat. The historical count is a lower bound that excludes drugs never developed because regulation made them uneconomic.
The Price of Political Change145	The budget ceiling for buying enough legal democratic pressure to make reform happen.	Total campaign cost: $1B; ~$25B U.S. ceiling; ~$200B global ceiling; >400,000:1 ROI for military-to-health reallocation	The ceiling is deliberately pessimistic: it assumes matching opposition spending and offering career alternatives rather than assuming voters or legislators become saints.
United States Efficiency Audit146	A concrete waste map showing where immediate reallocations can be found.	$4.9T (95% CI: $3.62T-$6.5T)/year efficiency gap; $2.45T (95% CI: $1.81T-$3.25T) recoverable capital; ~180 (95% CI: 133-239)x treaty funding	The estimate is not one giant hand-wave; it is a ten-component OECD-benchmarked Monte Carlo across direct waste, compliance burden, policy-induced GDP loss, and system inefficiency.
Optimocracy140	The recommendation layer that compares jurisdictions and tells you which policies work.	Cross-jurisdiction causal recommendation engine; politician-alignment tracking tied to campaign support	The data source is real policy variation across thousands of jurisdictions over decades, so the mechanism exploits an existing natural experiment instead of waiting for perfect centralized trials.
The Optimal Policy Generator141	The law-level engine for ENACT, REPLACE, REPEAL, and MAINTAIN decisions.	Policy Impact Score (PIS); four-action system with blocking-factor constraints; projected 5-15% of GDP welfare gains for typical U.S. states	The benchmark is grounded in standard quasi-experimental methods, Bradford Hill screening, and explicit freedom/autonomy blockers rather than black-box policy mysticism.
The Optimal Budget Generator142	The spending-level engine for reallocating money from weak programs to strong ones.	Budget Impact Score (BIS); 20-40% of public-goods funding misallocated relative to evidence-based benchmarks	The claim comes from combining causal evidence with diminishing-returns modeling, which is exactly what ordinary budget processes usually omit.
The Continuous Evidence Generation Protocol147	The medical evidence-production machine that keeps learning after the initial reform wins.	Stage 1 at $0.1 (95% CI: $0.03-$1)/patient; Stage 2 at $929 (95% CI: $97-$3K)/patient; 44.1x (95% CI: 39.4x-89.1x) cheaper than traditional Phase III; minimum data quality of >=5 predictor changes, >=5 outcome changes, and >=30 overlapping pairs	The cost anchors come from a meta-analysis of 108 pragmatic trials and real implementations such as RECOVERY and ADAPTABLE, not from hypothetical software-era wishcasting.
Right to Trial & FDA Upgrade Act	The statutory implementation path for opening the regulatory bottleneck.	Conditional patient access post-Phase I; removes the 8.2 (95% CI: 4.85-11.5)-year efficacy lag; timelines of 180 days, 1 year, and 18 months	Conditional access after Phase I safety data eliminates the 8.2 (95% CI: 4.85-11.5)-year gap between proving a drug works and allowing patients to use it. The mechanism is statutory, not speculative: it translates measured delay into rights, deadlines, and open-data obligations.
How to End War and Disease	The integrated narrative and coalition-building wrapper around the complete Earth Optimization Plan.	Earth Optimization Plan-wide coordination at total cost of $1B; 1% (95% CI: 0.1%-10%) estimated success probability	This is the sequencing and coalition wrapper, so its support comes from the already-costed modules rather than an independent giant welfare claim.
Drug Development Cost Increase Analysis72	The proof that current regulatory structure is not merely slow but catastrophically expensive.	105x (95% CI: 90.6x-119x) cost increase since pre-1962; current average: $2.6B (95% CI: $1.5B-$4B)/drug	The estimate is anchored to Baily (1972), inflation-adjusted to present dollars, and then cross-checked against six real-world comparisons, with outside estimates in the same 100-400x range.

The large numbers in this table come from three ordinary facts: existing waste pools are already measured in trillions, regulatory delay compounds over years and across billions of people, and pragmatic evidence generation is dramatically cheaper than the legacy trial stack. Each benchmark is traceable to a concrete mechanism, denominator, and empirical anchor.

In other words, the prize does not replace the Earth Optimization Plan. It sits above it and asks: which complete package of functions wins on verified welfare per dollar? If the answer is “this bundle,” then this bundle gets implemented. If the answer is “this bundle plus one missing module,” then the augmented bundle gets implemented. If the answer is “a different module set dominates row by row,” then the prize funds the better design instead.

That is exactly what you want from an honest optimization process.

The Selection Pipeline

The steps are simple:

1. Diagnose the waste. Use the dysfunction⁴⁶ and efficiency¹⁴⁶ papers to identify the largest pools of low-value spending and the harm caused by delay.
2. Generate candidate reallocations. Use Optimocracy¹⁴⁰, OPG¹⁴¹, and OBG¹⁴² to propose the best available moves under real-world constraints.
3. Apply sentient-welfare guardrails. Throw out plans that improve one metric by increasing suffering elsewhere.
4. Aggregate preference intensity. Use Wishocracy¹³⁹ to learn what tradeoffs the public actually prefers once the options are legible.
5. Finance adoption. The winning plan must include its own financing mechanism (the current candidate uses IAB-style structures¹³⁸) to raise the capital needed to pass the highest-ranked package.
6. Implement in the highest-ROI domain first. At current margins that is likely medical evidence generation: pragmatic trials¹⁴³, right to trial, FDA upgrade, and continuous evidence generation¹⁴⁷.
7. Reinvest recovered value. Once a high-ROI reform starts paying, the prize treasury expands and finances the next set of reallocations.

That loop is how you get from “good idea” to “a government improvement that pays for itself.”

Failover Ladder

For the Earth Optimization Plan or something better to feel inevitable, the prize cannot depend on one heroic legislative roll of the dice. It needs a failover ladder.

If the top-ranked path stalls, the treasury should automatically route capital to the next-highest admissible binding path in roughly this order:

1. treaty or national statute
2. agency rule, procurement rule, or enforcement-policy change
3. state-level legislation, interstate compact, or ballot measure
4. hospital-system, insurer, philanthropic, or employer-network adoption with auditable contractual obligations
5. narrower pilot pathways that still create legally durable precedent or reusable implementation infrastructure

The governing principle is simple: capital may move down the ladder, but it may not sit idle. If a higher rung becomes feasible later, the machine may move back up. If a rival package beats the current winner at any rung while remaining complete and admissible, support migrates there instead.

That is how you turn “if this path fails, try something else” into something that actually moves forward rather than a motivational slogan.

A challenger is free to beat the current papers. It just has to beat the Minimum Acceptable Governance row by row, or replace each row with a dominating substitute, and then produce better terminal outcomes (health and income) per dollar.

Why This Logically Leads to These Ideas or Better

There are only three stable outcomes:

1. The Earth Optimization Plan is best. Then the prize selects the full Minimum Acceptable Governance, finances it, and implements it because \(M_{complete} = 1\) is required and nothing beats it row by row.
2. The Earth Optimization Plan is mostly right but incomplete. Then the prize selects an augmented version of it, which still implements the existing modules while adding whatever missing function performs better.
3. A strict improvement exists. Then the prize selects that instead, but only if it dominates the Minimum Acceptable Governance function by function rather than skipping inconvenient pieces.

Those are the only serious possibilities. The unserious possibility is the one humans choose by default: endless argument with no implementation market.

Health economics, public choice theory, mechanism design, and game theory independently point to the same structure. When independent fields converge on a design, agreement is itself evidence. The bottleneck is not technology, willingness, or politics. It is the speed at which this information reaches people who can act on it.

The Actual Objective Function

If you want the short version, it is this:

Reward the first mechanism that can legally and durably implement every required function in the Minimum Acceptable Governance, or replace each one with a dominating substitute, while reallocating resources from their lowest net societal value uses to their highest ones, minimizing suffering, improving median health and wealth, and making every major affected class of living or sentient beings better off on net.

Everything else is just plumbing. And because the mechanism does not care where the suffering comes from, as human disease cost-per-DALY rises with diminishing returns, the system naturally moves capital to wherever suffering can be reduced most cheaply, whether that is neglected tropical diseases, factory farming, or ecosystem collapse.

That extension should be read cautiously, not mystically. The prize should only pivot beyond human disease where measurement, verification, and class-by-class welfare accounting are strong enough to clear the same admissibility tests. The point is not to authorize speculative interventions on nonhuman systems with weak evidence. The point is that once a domain can be measured rigorously enough, the prize should not remain trapped in more expensive human interventions merely because they are familiar.

And yes, this is still compatible with public choice theory, because the prize turns “find the least bad idea” into a competition for money, power, reputation, and durable institutional control. Your species already runs on those four fuels. The only change proposed here is to stop directing them at things that explode.

Conclusion

If this project is right, the prize causes its implementation. If this project is wrong, the prize discovers the better version and causes that implementation instead.

Either way, the feedback loop runs: more capital funds sharper selection, sharper selection funds better implementation, better implementation recovers more value, recovered value funds more capital. The mechanism does not need participants to be wise. It needs them to be greedy, impatient, and capable of reading a scoreboard.

The prize does not ask anyone to become good. It just makes doing nothing more expensive than doing something.

The mechanism is: stop arguing about which idea is best and build a market that pays for whichever one actually works. The rest is implementation.

The remaining variable is how long this takes to become obvious enough to act on.

References

1.

NIH Common Fund. NIH pragmatic trials: Minimal funding despite 30x cost advantage. NIH Common Fund: HCS Research Collaboratory https://commonfund.nih.gov/hcscollaboratory (2025)

The NIH Pragmatic Trials Collaboratory funds trials at $500K for planning phase, $1M/year for implementation-a tiny fraction of NIH’s budget. The ADAPTABLE trial cost $14 million for 15,076 patients (= $929/patient) versus $420 million for a similar traditional RCT (30x cheaper), yet pragmatic trials remain severely underfunded. PCORnet infrastructure enables real-world trials embedded in healthcare systems, but receives minimal support compared to basic research funding. Additional sources: https://commonfund.nih.gov/hcscollaboratory | https://pcornet.org/wp-content/uploads/2025/08/ADAPTABLE_Lay_Summary_21JUL2025.pdf | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604499/

.

2.

NIH. Antidepressant clinical trial exclusion rates. Zimmerman et al. https://pubmed.ncbi.nlm.nih.gov/26276679/ (2015)

Mean exclusion rate: 86.1% across 158 antidepressant efficacy trials (range: 44.4% to 99.8%) More than 82% of real-world depression patients would be ineligible for antidepressant registration trials Exclusion rates increased over time: 91.4% (2010-2014) vs. 83.8% (1995-2009) Most common exclusions: comorbid psychiatric disorders, age restrictions, insufficient depression severity, medical conditions Emergency psychiatry patients: only 3.3% eligible (96.7% excluded) when applying 9 common exclusion criteria Only a minority of depressed patients seen in clinical practice are likely to be eligible for most AETs Note: Generalizability of antidepressant trials has decreased over time, with increasingly stringent exclusion criteria eliminating patients who would actually use the drugs in clinical practice Additional sources: https://pubmed.ncbi.nlm.nih.gov/26276679/ | https://pubmed.ncbi.nlm.nih.gov/26164052/ | https://www.wolterskluwer.com/en/news/antidepressant-trials-exclude-most-real-world-patients-with-depression

.

3.

CNBC. Warren buffett’s career average investment return. CNBC https://www.cnbc.com/2025/05/05/warren-buffetts-return-tally-after-60-years-5502284percent.html (2025)

Berkshire’s compounded annual return from 1965 through 2024 was 19.9%, nearly double the 10.4% recorded by the S&P 500. Berkshire shares skyrocketed 5,502,284% compared to the S&P 500’s 39,054% rise during that period. Additional sources: https://www.cnbc.com/2025/05/05/warren-buffetts-return-tally-after-60-years-5502284percent.html | https://www.slickcharts.com/berkshire-hathaway/returns

.

4.

World Health Organization. WHO global health estimates 2024. World Health Organization https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates (2024)

Comprehensive mortality and morbidity data by cause, age, sex, country, and year Global mortality:  55-60 million deaths annually Lives saved by modern medicine (vaccines, cardiovascular drugs, oncology):  12M annually (conservative aggregate) Leading causes of death: Cardiovascular disease (17.9M), Cancer (10.3M), Respiratory disease (4.0M) Note: Baseline data for regulatory mortality analysis. Conservative estimate of pharmaceutical impact based on WHO immunization data (4.5M/year from vaccines) + cardiovascular interventions (3.3M/year) + oncology (1.5M/year) + other therapies. Additional sources: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates

.

5.

GiveWell. GiveWell cost per life saved for top charities (2024). GiveWell: Top Charities https://www.givewell.org/charities/top-charities

General range: $3,000-$5,500 per life saved (GiveWell top charities) Helen Keller International (Vitamin A): $3,500 average (2022-2024); varies $1,000-$8,500 by country Against Malaria Foundation: $5,500 per life saved New Incentives (vaccination incentives): $4,500 per life saved Malaria Consortium (seasonal malaria chemoprevention):  $3,500 per life saved VAS program details:  $2 to provide vitamin A supplements to child for one year Note: Figures accurate for 2024. Helen Keller VAS program has wide country variation ($1K-$8.5K) but $3,500 is accurate average. Among most cost-effective interventions globally Additional sources: https://www.givewell.org/charities/top-charities | https://www.givewell.org/charities/helen-keller-international | https://ourworldindata.org/cost-effectiveness

.

6.

AARP. Unpaid caregiver hours and economic value. AARP 2023 https://www.aarp.org/caregiving/financial-legal/info-2023/unpaid-caregivers-provide-billions-in-care.html (2023)

Average family caregiver: 25-26 hours per week (100-104 hours per month) 38 million caregivers providing 36 billion hours of care annually Economic value: $16.59 per hour = $600 billion total annual value (2021) 28% of people provided eldercare on a given day, averaging 3.9 hours when providing care Caregivers living with care recipient: 37.4 hours per week Caregivers not living with recipient: 23.7 hours per week Note: Disease-related caregiving is subset of total; includes elderly care, disability care, and child care Additional sources: https://www.aarp.org/caregiving/financial-legal/info-2023/unpaid-caregivers-provide-billions-in-care.html | https://www.bls.gov/news.release/elcare.nr0.htm | https://www.caregiver.org/resource/caregiver-statistics-demographics/

.

7.

Forbes. Forbes world’s billionaires list 2024. (2024)

Forbes identified a record 2,781 billionaires worldwide with combined net worth of $14.2 trillion, 141 more than 2023. Bernard Arnault (LVMH) topped the list at $233 billion.

8.

CDC MMWR. Childhood vaccination economic benefits. CDC MMWR https://www.cdc.gov/mmwr/volumes/73/wr/mm7331a2.htm (1994)

US programs (1994-2023): $540B direct savings, $2.7T societal savings ( $18B/year direct,  $90B/year societal) Global (2001-2020): $820B value for 10 diseases in 73 countries ( $41B/year) ROI: $11 return per $1 invested Measles vaccination alone saved 93.7M lives (61% of 154M total) over 50 years (1974-2024) Additional sources: https://www.cdc.gov/mmwr/volumes/73/wr/mm7331a2.htm | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00850-X/fulltext

.

9.

CDC. Childhood vaccination (US) ROI. CDC https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6316a4.htm (2017).

10.

U.S. Bureau of Labor Statistics. CPI inflation calculator. (2024)

CPI-U (1980): 82.4 CPI-U (2024): 313.5 Inflation multiplier (1980-2024): 3.80× Cumulative inflation: 280.48% Average annual inflation rate: 3.08% Note: Official U.S. government inflation data using Consumer Price Index for All Urban Consumers (CPI-U). Additional sources: https://www.bls.gov/data/inflation_calculator.htm

.

11.

ClinicalTrials.gov API v2 direct analysis. ClinicalTrials.gov cumulative enrollment data (2025). Direct analysis via ClinicalTrials.gov API v2 https://clinicaltrials.gov/data-api/api

Analysis of 100,000 active/recruiting/completed trials on ClinicalTrials.gov (as of January 2025) shows cumulative enrollment of 12.2 million participants: Phase 1 (722k), Phase 2 (2.2M), Phase 3 (6.5M), Phase 4 (2.7M). Median participants per trial: Phase 1 (33), Phase 2 (60), Phase 3 (237), Phase 4 (90). Additional sources: https://clinicaltrials.gov/data-api/api

.

12.

ACS CAN. Clinical trial patient participation rate. ACS CAN: Barriers to Clinical Trial Enrollment https://www.fightcancer.org/policy-resources/barriers-patient-enrollment-therapeutic-clinical-trials-cancer

Only 3-5% of adult cancer patients in US receive treatment within clinical trials About 5% of American adults have ever participated in any clinical trial Oncology: 2-3% of all oncology patients participate Contrast: 50-60% enrollment for pediatric cancer trials (<15 years old) Note:  20% of cancer trials fail due to insufficient enrollment; 11% of research sites enroll zero patients Additional sources: https://www.fightcancer.org/policy-resources/barriers-patient-enrollment-therapeutic-clinical-trials-cancer | https://hints.cancer.gov/docs/Briefs/HINTS_Brief_48.pdf

.

13.

ScienceDaily. Global prevalence of chronic disease. ScienceDaily: GBD 2015 Study https://www.sciencedaily.com/releases/2015/06/150608081753.htm (2015)

2.3 billion individuals had more than five ailments (2013) Chronic conditions caused 74% of all deaths worldwide (2019), up from 67% (2010) Approximately 1 in 3 adults suffer from multiple chronic conditions (MCCs) Risk factor exposures: 2B exposed to biomass fuel, 1B to air pollution, 1B smokers Projected economic cost: $47 trillion by 2030 Note: 2.3B with 5+ ailments is more accurate than "2B with chronic disease." One-third of all adults globally have multiple chronic conditions Additional sources: https://www.sciencedaily.com/releases/2015/06/150608081753.htm | https://pmc.ncbi.nlm.nih.gov/articles/PMC10830426/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC6214883/

.

14.

C&EN. Annual number of new drugs approved globally:  50. C&EN https://cen.acs.org/pharmaceuticals/50-new-drugs-received-FDA/103/i2 (2025)

50 new drugs approved annually Additional sources: https://cen.acs.org/pharmaceuticals/50-new-drugs-received-FDA/103/i2 | https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda

.

15.

Williams, R. J., Tse, T., DiPiazza, K. & Zarin, D. A. Terminated trials in the ClinicalTrials.gov results database: Evaluation of availability of primary outcome data and reasons for termination. PLOS One 10, e0127242 (2015)

Approximately 12% of trials with results posted on the ClinicalTrials.gov results database (905/7,646) were terminated. Primary reasons: insufficient accrual (57% of non-data-driven terminations), business/strategic reasons, and efficacy/toxicity findings (21% data-driven terminations).

16.

IQVIA Report. Global trial capacity. IQVIA Report: Clinical Trial Subjects Number Drops Due to Decline in COVID-19 Enrollment https://gmdpacademy.org/news/iqvia-report-clinical-trial-subjects-number-drops-due-to-decline-in-covid-19-enrollment/

1.9M participants annually (2022, post-COVID normalization from 4M peak in 2021) Additional sources: https://gmdpacademy.org/news/iqvia-report-clinical-trial-subjects-number-drops-due-to-decline-in-covid-19-enrollment/

.

17.

Research and Markets. Global clinical trials market 2024. Research and Markets https://www.globenewswire.com/news-release/2024/04/19/2866012/0/en/Global-Clinical-Trials-Market-Research-Report-2024-An-83-16-Billion-Market-by-2030-AI-Machine-Learning-and-Blockchain-will-Transform-the-Clinical-Trials-Landscape.html (2024)

Global clinical trials market valued at approximately $83 billion in 2024, with projections to reach $83-132 billion by 2030. Additional sources: https://www.globenewswire.com/news-release/2024/04/19/2866012/0/en/Global-Clinical-Trials-Market-Research-Report-2024-An-83-16-Billion-Market-by-2030-AI-Machine-Learning-and-Blockchain-will-Transform-the-Clinical-Trials-Landscape.html | https://www.precedenceresearch.com/clinical-trials-market

.

18.

OpenSecrets. Lobbying spend (defense). OpenSecrets https://www.opensecrets.org/industries/lobbying?ind=D (2024).

19.

GiveWell. Cost per DALY for deworming programs. https://www.givewell.org/international/technical/programs/deworming/cost-effectiveness

Schistosomiasis treatment: $28.19-$70.48 per DALY (using arithmetic means with varying disability weights) Soil-transmitted helminths (STH) treatment: $82.54 per DALY (midpoint estimate) Note: GiveWell explicitly states this 2011 analysis is "out of date" and their current methodology focuses on long-term income effects rather than short-term health DALYs Additional sources: https://www.givewell.org/international/technical/programs/deworming/cost-effectiveness

.

20.

Calculated from IHME Global Burden of Disease (2.55B DALYs) and global GDP per capita valuation. $109 trillion annual global disease burden.

The global economic burden of disease, including direct healthcare costs ($8.2 trillion) and lost productivity ($100.9 trillion from 2.55 billion DALYs × $39,570 per DALY), totals approximately $109.1 trillion annually.

21.

U.S. Department of Transportation. Departmental guidance on valuation of a statistical life in economic analysis. (2024).

22.

Think by Numbers. Pre-1962 drug development costs and timeline (think by numbers). Think by Numbers: How Many Lives Does FDA Save? https://thinkbynumbers.org/health/how-many-net-lives-does-the-fda-save/ (1962)

Historical estimates (1970-1985): USD $226M fully capitalized (2011 prices) 1980s drugs:  $65M after-tax R&D (1990 dollars),  $194M compounded to approval (1990 dollars) Modern comparison: $2-3B costs, 7-12 years (dramatic increase from pre-1962) Context: 1962 regulatory clampdown reduced new treatment production by 70%, dramatically increasing development timelines and costs Note: Secondary source; less reliable than Congressional testimony Additional sources: https://thinkbynumbers.org/health/how-many-net-lives-does-the-fda-save/ | https://en.wikipedia.org/wiki/Cost_of_drug_development | https://www.statnews.com/2018/10/01/changing-1962-law-slash-drug-prices/

.

23.

Biotechnology Innovation Organization (BIO). BIO clinical development success rates 2011-2020. Biotechnology Innovation Organization (BIO) https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf (2021)

Phase I duration: 2.3 years average Total time to market (Phase I-III + approval): 10.5 years average Phase transition success rates: Phase I→II: 63.2%, Phase II→III: 30.7%, Phase III→Approval: 58.1% Overall probability of approval from Phase I: 12% Note: Largest publicly available study of clinical trial success rates. Efficacy lag = 10.5 - 2.3 = 8.2 years post-safety verification. Additional sources: https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf

.

24.

Nature Medicine. Drug repurposing rate ( 30%). Nature Medicine https://www.nature.com/articles/s41591-024-03233-x (2024)

Approximately 30% of drugs gain at least one new indication after initial approval. Additional sources: https://www.nature.com/articles/s41591-024-03233-x

.

25.

EPI. Education investment economic multiplier (2.1). EPI: Public Investments Outside Core Infrastructure https://www.epi.org/publication/bp348-public-investments-outside-core-infrastructure/

Early childhood education: Benefits 12X outlays by 2050; $8.70 per dollar over lifetime Educational facilities: $1 spent → $1.50 economic returns Energy efficiency comparison: 2-to-1 benefit-to-cost ratio (McKinsey) Private return to schooling:  9% per additional year (World Bank meta-analysis) Note: 2.1 multiplier aligns with benefit-to-cost ratios for educational infrastructure/energy efficiency. Early childhood education shows much higher returns (12X by 2050) Additional sources: https://www.epi.org/publication/bp348-public-investments-outside-core-infrastructure/ | https://documents1.worldbank.org/curated/en/442521523465644318/pdf/WPS8402.pdf | https://freopp.org/whitepapers/establishing-a-practical-return-on-investment-framework-for-education-and-skills-development-to-expand-economic-opportunity/

.

26.

PMC. Healthcare investment economic multiplier (1.8). PMC: California Universal Health Care https://pmc.ncbi.nlm.nih.gov/articles/PMC5954824/ (2022)

Healthcare fiscal multiplier: 4.3 (95% CI: 2.5-6.1) during pre-recession period (1995-2007) Overall government spending multiplier: 1.61 (95% CI: 1.37-1.86) Why healthcare has high multipliers: No effect on trade deficits (spending stays domestic); improves productivity & competitiveness; enhances long-run potential output Gender-sensitive fiscal spending (health & care economy) produces substantial positive growth impacts Note: "1.8" appears to be conservative estimate; research shows healthcare multipliers of 4.3 Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC5954824/ | https://cepr.org/voxeu/columns/government-investment-and-fiscal-stimulus | https://ncbi.nlm.nih.gov/pmc/articles/PMC3849102/ | https://set.odi.org/wp-content/uploads/2022/01/Fiscal-multipliers-review.pdf

.

27.

World Bank. Infrastructure investment economic multiplier (1.6). World Bank: Infrastructure Investment as Stimulus https://blogs.worldbank.org/en/ppps/effectiveness-infrastructure-investment-fiscal-stimulus-what-weve-learned (2022)

Infrastructure fiscal multiplier:  1.6 during contractionary phase of economic cycle Average across all economic states:  1.5 (meaning $1 of public investment → $1.50 of economic activity) Time horizon: 0.8 within 1 year,  1.5 within 2-5 years Range of estimates: 1.5-2.0 (following 2008 financial crisis & American Recovery Act) Italian public construction: 1.5-1.9 multiplier US ARRA: 0.4-2.2 range (differential impacts by program type) Economic Policy Institute: Uses 1.6 for infrastructure spending (middle range of estimates) Note: Public investment less likely to crowd out private activity during recessions; particularly effective when monetary policy loose with near-zero rates Additional sources: https://blogs.worldbank.org/en/ppps/effectiveness-infrastructure-investment-fiscal-stimulus-what-weve-learned | https://www.gihub.org/infrastructure-monitor/insights/fiscal-multiplier-effect-of-infrastructure-investment/ | https://cepr.org/voxeu/columns/government-investment-and-fiscal-stimulus | https://www.richmondfed.org/publications/research/economic_brief/2022/eb_22-04

.

28.

Mercatus. Military spending economic multiplier (0.6). Mercatus: Defense Spending and Economy https://www.mercatus.org/research/research-papers/defense-spending-and-economy

Ramey (2011):  0.6 short-run multiplier Barro (1981): 0.6 multiplier for WWII spending (war spending crowded out  40¢ private economic activity per federal dollar) Barro & Redlick (2011): 0.4 within current year, 0.6 over two years; increased govt spending reduces private-sector GDP portions General finding: $1 increase in deficit-financed federal military spending = less than $1 increase in GDP Variation by context: Central/Eastern European NATO: 0.6 on impact, 1.5-1.6 in years 2-3, gradual fall to zero Ramey & Zubairy (2018): Cumulative 1% GDP increase in military expenditure raises GDP by  0.7% Additional sources: https://www.mercatus.org/research/research-papers/defense-spending-and-economy | https://cepr.org/voxeu/columns/world-war-ii-america-spending-deficits-multipliers-and-sacrifice | https://www.rand.org/content/dam/rand/pubs/research_reports/RRA700/RRA739-2/RAND_RRA739-2.pdf

.

29.

FDA. FDA-approved prescription drug products (20,000+). FDA https://www.fda.gov/media/143704/download

There are over 20,000 prescription drug products approved for marketing. Additional sources: https://www.fda.gov/media/143704/download

.

30.

FDA. FDA GRAS list count ( 570-700). FDA https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory

The FDA GRAS (Generally Recognized as Safe) list contains approximately 570–700 substances. Additional sources: https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory

.

31.

ACLED. Active combat deaths annually. ACLED: Global Conflict Surged 2024 https://acleddata.com/2024/12/12/data-shows-global-conflict-surged-in-2024-the-washington-post/ (2024)

2024: 233,597 deaths (30% increase from 179,099 in 2023) Deadliest conflicts: Ukraine (67,000), Palestine (35,000) Nearly 200,000 acts of violence (25% higher than 2023, double from 5 years ago) One in six people globally live in conflict-affected areas Additional sources: https://acleddata.com/2024/12/12/data-shows-global-conflict-surged-in-2024-the-washington-post/ | https://acleddata.com/media-citation/data-shows-global-conflict-surged-2024-washington-post | https://acleddata.com/conflict-index/index-january-2024/

.

32.

UCDP. State violence deaths annually. UCDP: Uppsala Conflict Data Program https://ucdp.uu.se/

Uppsala Conflict Data Program (UCDP): Tracks one-sided violence (organized actors attacking unarmed civilians) UCDP definition: Conflicts causing at least 25 battle-related deaths in calendar year 2023 total organized violence: 154,000 deaths; Non-state conflicts: 20,900 deaths UCDP collects data on state-based conflicts, non-state conflicts, and one-sided violence Specific "2,700 annually" figure for state violence not found in recent UCDP data; actual figures vary annually Additional sources: https://ucdp.uu.se/ | https://en.wikipedia.org/wiki/Uppsala_Conflict_Data_Program | https://ourworldindata.org/grapher/deaths-in-armed-conflicts-by-region

.

33.

Our World in Data. Terror attack deaths (8,300 annually). Our World in Data: Terrorism https://ourworldindata.org/terrorism (2024)

2023: 8,352 deaths (22% increase from 2022, highest since 2017) 2023: 3,350 terrorist incidents (22% decrease), but 56% increase in avg deaths per attack Global Terrorism Database (GTD): 200,000+ terrorist attacks recorded (2021 version) Maintained by: National Consortium for Study of Terrorism & Responses to Terrorism (START), U. of Maryland Geographic shift: Epicenter moved from Middle East to Central Sahel (sub-Saharan Africa) - now >50% of all deaths Additional sources: https://ourworldindata.org/terrorism | https://reliefweb.int/report/world/global-terrorism-index-2024 | https://www.start.umd.edu/gtd/ | https://ourworldindata.org/grapher/fatalities-from-terrorism

.

34.

Institute for Health Metrics and Evaluation (IHME). IHME global burden of disease 2021 (2.88B DALYs, 1.13B YLD). Institute for Health Metrics and Evaluation (IHME) https://vizhub.healthdata.org/gbd-results/ (2024)

In 2021, global DALYs totaled approximately 2.88 billion, comprising 1.75 billion Years of Life Lost (YLL) and 1.13 billion Years Lived with Disability (YLD). This represents a 13% increase from 2019 (2.55B DALYs), largely attributable to COVID-19 deaths and aging populations. YLD accounts for approximately 39% of total DALYs, reflecting the substantial burden of non-fatal chronic conditions. Additional sources: https://vizhub.healthdata.org/gbd-results/ | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00757-8/fulltext | https://www.healthdata.org/research-analysis/about-gbd

.

35.

Costs of War Project, Brown University Watson Institute. Environmental cost of war ($100B annually). Brown Watson Costs of War: Environmental Cost https://watson.brown.edu/costsofwar/costs/social/environment

War on Terror emissions: 1.2B metric tons GHG (equivalent to 257M cars/year) Military: 5.5% of global GHG emissions (2X aviation + shipping combined) US DoD: World’s single largest institutional oil consumer, 47th largest emitter if nation Cleanup costs: $500B+ for military contaminated sites Gaza war environmental damage: $56.4B; landmine clearance: $34.6B expected Climate finance gap: Rich nations spend 30X more on military than climate finance Note: Military activities cause massive environmental damage through GHG emissions, toxic contamination, and long-term cleanup costs far exceeding current climate finance commitments Additional sources: https://watson.brown.edu/costsofwar/costs/social/environment | https://earth.org/environmental-costs-of-wars/ | https://transformdefence.org/transformdefence/stats/

.

36.

ScienceDaily. Medical research lives saved annually (4.2 million). ScienceDaily: Physical Activity Prevents 4M Deaths https://www.sciencedaily.com/releases/2020/06/200617194510.htm (2020)

Physical activity: 3.9M early deaths averted annually worldwide (15% lower premature deaths than without) COVID vaccines (2020-2024): 2.533M deaths averted, 14.8M life-years preserved; first year alone: 14.4M deaths prevented Cardiovascular prevention: 3 interventions could delay 94.3M deaths over 25 years (antihypertensives alone: 39.4M) Pandemic research response: Millions of deaths averted through rapid vaccine/drug development Additional sources: https://www.sciencedaily.com/releases/2020/06/200617194510.htm | https://pmc.ncbi.nlm.nih.gov/articles/PMC9537923/ | https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.038160 | https://pmc.ncbi.nlm.nih.gov/articles/PMC9464102/

.

37.

SIPRI. 36:1 disparity ratio of spending on weapons over cures. SIPRI: Military Spending https://www.sipri.org/commentary/blog/2016/opportunity-cost-world-military-spending (2016)

Global military spending: $2.7 trillion (2024, SIPRI) Global government medical research:  $68 billion (2024) Actual ratio: 39.7:1 in favor of weapons over medical research Military R&D alone:  $85B (2004 data, 10% of global R&D) Military spending increases crowd out health: 1% ↑ military = 0.62% ↓ health spending Note: Ratio actually worse than 36:1. Each 1% increase in military spending reduces health spending by 0.62%, with effect more intense in poorer countries (0.962% reduction) Additional sources: https://www.sipri.org/commentary/blog/2016/opportunity-cost-world-military-spending | https://pmc.ncbi.nlm.nih.gov/articles/PMC9174441/ | https://www.congress.gov/crs-product/R45403

.

38.

Think by Numbers. Lost human capital due to war ($270B annually). Think by Numbers https://thinkbynumbers.org/military/war/the-economic-case-for-peace-a-comprehensive-financial-analysis/ (2021)

Lost human capital from war: $300B annually (economic impact of losing skilled/productive individuals to conflict) Broader conflict/violence cost: $14T/year globally 1.4M violent deaths/year; conflict holds back economic development, causes instability, widens inequality, erodes human capital 2002: 48.4M DALYs lost from 1.6M violence deaths = $151B economic value (2000 USD) Economic toll includes: commodity prices, inflation, supply chain disruption, declining output, lost human capital Additional sources: https://thinkbynumbers.org/military/war/the-economic-case-for-peace-a-comprehensive-financial-analysis/ | https://www.weforum.org/stories/2021/02/war-violence-costs-each-human-5-a-day/ | https://pubmed.ncbi.nlm.nih.gov/19115548/

.

39.

PubMed. Psychological impact of war cost ($100B annually). PubMed: Economic Burden of PTSD https://pubmed.ncbi.nlm.nih.gov/35485933/

PTSD economic burden (2018 U.S.): $232.2B total ($189.5B civilian, $42.7B military) Civilian costs driven by: Direct healthcare ($66B), unemployment ($42.7B) Military costs driven by: Disability ($17.8B), direct healthcare ($10.1B) Exceeds costs of other mental health conditions (anxiety, depression) War-exposed populations: 2-3X higher rates of anxiety, depression, PTSD; women and children most vulnerable Note: Actual burden $232B, significantly higher than "$100B" claimed Additional sources: https://pubmed.ncbi.nlm.nih.gov/35485933/ | https://news.va.gov/103611/study-national-economic-burden-of-ptsd-staggering/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9957523/

.

40.

CGDev. UNHCR average refugee support cost. CGDev https://www.cgdev.org/blog/costs-hosting-refugees-oecd-countries-and-why-uk-outlier (2024)

The average cost of supporting a refugee is $1,384 per year. This represents total host country costs (housing, healthcare, education, security). OECD countries average $6,100 per refugee (mean 2022-2023), with developing countries spending $700-1,000. Global weighted average of  $1,384 is reasonable given that 75-85% of refugees are in low/middle-income countries. Additional sources: https://www.cgdev.org/blog/costs-hosting-refugees-oecd-countries-and-why-uk-outlier | https://www.unhcr.org/sites/default/files/2024-11/UNHCR-WB-global-cost-of-refugee-inclusion-in-host-country-health-systems.pdf

.

41.

World Bank. World bank trade disruption cost from conflict. World Bank https://www.worldbank.org/en/topic/trade/publication/trading-away-from-conflict

Estimated $616B annual cost from conflict-related trade disruption. World Bank research shows civil war costs an average developing country 30 years of GDP growth, with 20 years needed for trade to return to pre-war levels. Trade disputes analysis shows tariff escalation could reduce global exports by up to $674 billion. Additional sources: https://www.worldbank.org/en/topic/trade/publication/trading-away-from-conflict | https://www.nber.org/papers/w11565 | http://blogs.worldbank.org/en/trade/impacts-global-trade-and-income-current-trade-disputes

.

42.

VA. Veteran healthcare cost projections. VA https://department.va.gov/wp-content/uploads/2025/06/2026-Budget-in-Brief.pdf (2026)

VA budget: $441.3B requested for FY 2026 (10% increase). Disability compensation: $165.6B in FY 2024 for 6.7M veterans. PACT Act projected to increase spending by $300B between 2022-2031. Costs under Toxic Exposures Fund: $20B (2024), $30.4B (2025), $52.6B (2026). Additional sources: https://department.va.gov/wp-content/uploads/2025/06/2026-Budget-in-Brief.pdf | https://www.cbo.gov/publication/45615 | https://www.legion.org/information-center/news/veterans-healthcare/2025/june/va-budget-tops-400-billion-for-2025-from-higher-spending-on-mandated-benefits-medical-care

.

43.

IQVIA Institute for Human Data Science. The global use of medicines 2024: Outlook to 2028. IQVIA Institute Report https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2024-outlook-to-2028 (2024)

Global days of therapy reached 1.8 trillion in 2019 (234 defined daily doses per person). Diabetes, respiratory, CVD, and cancer account for 71 percent of medicine use. Projected to reach 3.8 trillion DDDs by 2028.

44.

Sinn, M. P. Private industry clinical trial spending estimate. (2025)

Estimated private pharmaceutical and biotech clinical trial spending is approximately $75-90 billion annually, representing roughly 90% of global clinical trial spending.

45.

Cybersecurity Ventures. Cybercrime economy projected to reach $10.5 trillion. Cybersecurity Ventures: $10.5T Cybercrime https://cybersecurityventures.com/hackerpocalypse-cybercrime-report-2016/ (2016)

Global cybercrime costs: $3T (2015) → $6T (2021) → $10.5T (2025 projected) 15% annual growth rate If measured as country, would be 3rd largest economy after US and China Greatest transfer of economic wealth in history Note: More profitable than global trade of all major illegal drugs combined. Includes data theft, productivity loss, IP theft, fraud Additional sources: <https://cybersecurityventures.com/hackerpocalypse-cybercrime-report-2016/> | https://www.boisestate.edu/cybersecurity/2022/06/16/cybercrime-to-cost-the-world-10-5-trillion-annually-by-2025/

.

46.

Sinn, M. P. The Political Dysfunction Tax. https://political-dysfunction-tax.warondisease.org (2025) doi:10.5281/zenodo.18603840

Quantifying the gap between current global governance and theoretical maximum welfare, estimating a 31-53% efficiency score and $97 trillion in annual opportunity costs.

47.

Applied Clinical Trials. Global government spending on interventional clinical trials:  $3-6 billion/year. Applied Clinical Trials https://www.appliedclinicaltrialsonline.com/view/sizing-clinical-research-market

Estimated range based on NIH ( $0.8-5.6B), NIHR ($1.6B total budget), and EU funding ( $1.3B/year). Roughly 5-10% of global market. Additional sources: https://www.appliedclinicaltrialsonline.com/view/sizing-clinical-research-market | https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30357-0/fulltext

.

48.

UBS. Credit suisse global wealth report 2023. Credit Suisse/UBS https://www.ubs.com/global/en/family-office-uhnw/reports/global-wealth-report-2023.html (2023)

Total global household wealth: USD 454.4 trillion (2022) Wealth declined by USD 11.3 trillion (-2.4%) in 2022, first decline since 2008 Wealth per adult: USD 84,718 Additional sources: https://www.ubs.com/global/en/family-office-uhnw/reports/global-wealth-report-2023.html

.

49.

Component country budgets. Global government medical research spending ($67.5B, 2023–2024). See component country budgets: NIH Budget https://www.nih.gov/about-nih/what-we-do/budget.

50.

United Nations Department of Economic and Social Affairs, Population Division. World population prospects 2024: Summary of results. (2024)

The 2024 Revision of the World Population Prospects provides population estimates and projections for 237 countries or areas. Global median age approximately 30.5 years in 2024, reflecting population-weighted average across all regions.

51.

SIPRI. Global military spending ($2.72T, 2024). SIPRI https://www.sipri.org/publications/2025/sipri-fact-sheets/trends-world-military-expenditure-2024 (2025).

52.

Stockholm International Peace Research Institute. Trends in world military expenditure, 2024. (2025).

53.

Estimated from major foundation budgets and activities. Nonprofit clinical trial funding estimate.

Nonprofit foundations spend an estimated $2-5 billion annually on clinical trials globally, representing approximately 2-5% of total clinical trial spending.

54.

Industry reports: IQVIA. Global pharmaceutical r&d spending.

Total global pharmaceutical R&D spending is approximately $300 billion annually. Clinical trials represent 15-20% of this total ($45-60B), with the remainder going to drug discovery, preclinical research, regulatory affairs, and manufacturing development.

55.

UN. Global population reaches 8 billion. UN: World Population 8 Billion Nov 15 2022 https://www.un.org/en/desa/world-population-reach-8-billion-15-november-2022 (2022)

Milestone: November 15, 2022 (UN World Population Prospects 2022) Day of Eight Billion" designated by UN Added 1 billion people in just 11 years (2011-2022) Growth rate: Slowest since 1950; fell under 1% in 2020 Future: 15 years to reach 9B (2037); projected peak 10.4B in 2080s Projections: 8.5B (2030), 9.7B (2050), 10.4B (2080-2100 plateau) Note: Milestone reached Nov 2022. Population growth slowing; will take longer to add next billion (15 years vs 11 years) Additional sources: https://www.un.org/en/desa/world-population-reach-8-billion-15-november-2022 | https://www.un.org/en/dayof8billion | https://en.wikipedia.org/wiki/Day_of_Eight_Billion

.

56.

Harvard Kennedy School. 3.5% participation tipping point. Harvard Kennedy School https://www.hks.harvard.edu/centers/carr/publications/35-rule-how-small-minority-can-change-world (2020)

The research found that nonviolent campaigns were twice as likely to succeed as violent ones, and once 3.5% of the population were involved, they were always successful. Chenoweth and Maria Stephan studied the success rates of civil resistance efforts from 1900 to 2006, finding that nonviolent movements attracted, on average, four times as many participants as violent movements and were more likely to succeed. Key finding: Every campaign that mobilized at least 3.5% of the population in sustained protest was successful (in their 1900-2006 dataset) Note: The 3.5% figure is a descriptive statistic from historical analysis, not a guaranteed threshold. One exception (Bahrain 2011-2014 with 6%+ participation) has been identified. The rule applies to regime change, not policy change in democracies. Additional sources: https://www.hks.harvard.edu/centers/carr/publications/35-rule-how-small-minority-can-change-world | https://www.hks.harvard.edu/sites/default/files/2024-05/Erica%20Chenoweth_2020-005.pdf | https://www.bbc.com/future/article/20190513-it-only-takes-35-of-people-to-change-the-world | https://en.wikipedia.org/wiki/3.5%25_rule

.

57.

NHGRI. Human genome project and CRISPR discovery. NHGRI https://www.genome.gov/11006929/2003-release-international-consortium-completes-hgp (2003)

Your DNA is 3 billion base pairs Read the entire code (Human Genome Project, completed 2003) Learned to edit it (CRISPR, discovered 2012) Additional sources: https://www.genome.gov/11006929/2003-release-international-consortium-completes-hgp | https://www.nobelprize.org/prizes/chemistry/2020/press-release/

.

58.

PMC. Only  12% of human interactome targeted. PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC10749231/ (2023)

Mapping 350,000+ clinical trials showed that only  12% of the human interactome has ever been targeted by drugs. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10749231/

.

59.

WHO. ICD-10 code count ( 14,000). WHO https://icd.who.int/browse10/2019/en (2019)

The ICD-10 classification contains approximately 14,000 codes for diseases, signs and symptoms. Additional sources: https://icd.who.int/browse10/2019/en

.

60.

Wikipedia. Longevity escape velocity (LEV) - maximum human life extension potential. Wikipedia: Longevity Escape Velocity https://en.wikipedia.org/wiki/Longevity_escape_velocity

Longevity escape velocity: Hypothetical point where medical advances extend life expectancy faster than time passes Term coined by Aubrey de Grey (biogerontologist) in 2004 paper; concept from David Gobel (Methuselah Foundation) Current progress: Science adds  3 months to lifespan per year; LEV requires adding >1 year per year Sinclair (Harvard): "There is no biological upper limit to age" - first person to live to 150 may already be born De Grey: 50% chance of reaching LEV by mid-to-late 2030s; SENS approach = damage repair rather than slowing damage Kurzweil (2024): LEV by 2029-2035, AI will simulate biological processes to accelerate solutions George Church: LEV "in a decade or two" via age-reversal clinical trials Natural lifespan cap:  120-150 years (Jeanne Calment record: 122); engineering approach could bypass via damage repair Key mechanisms: Epigenetic reprogramming, senolytic drugs, stem cell therapy, gene therapy, AI-driven drug discovery Current record: Jeanne Calment (122 years, 164 days) - record unbroken since 1997 Note: LEV is theoretical but increasingly plausible given demonstrated age reversal in mice (109% lifespan extension) and human cells (30-year epigenetic age reversal) Additional sources: https://en.wikipedia.org/wiki/Longevity_escape_velocity | https://pmc.ncbi.nlm.nih.gov/articles/PMC423155/ | https://www.popularmechanics.com/science/a36712084/can-science-cure-death-longevity/ | https://www.diamandis.com/blog/longevity-escape-velocity

.

61.

OpenSecrets. Lobbyist statistics for washington d.c. OpenSecrets: Lobbying in US https://en.wikipedia.org/wiki/Lobbying_in_the_United_States

Registered lobbyists: Over 12,000 (some estimates); 12,281 registered (2013) Former government employees as lobbyists: 2,200+ former federal employees (1998-2004), including 273 former White House staffers,  250 former Congress members & agency heads Congressional revolving door: 43% (86 of 198) lawmakers who left 1998-2004 became lobbyists; currently 59% leaving to private sector work for lobbying/consulting firms/trade groups Executive branch: 8% were registered lobbyists at some point before/after government service Additional sources: https://en.wikipedia.org/wiki/Lobbying_in_the_United_States | https://www.opensecrets.org/revolving-door | https://www.citizen.org/article/revolving-congress/ | https://www.propublica.org/article/we-found-a-staggering-281-lobbyists-whove-worked-in-the-trump-administration

.

62.

MDPI Vaccines. Measles vaccination ROI. MDPI Vaccines https://www.mdpi.com/2076-393X/12/11/1210 (2024)

Single measles vaccination: 167:1 benefit-cost ratio. MMR (measles-mumps-rubella) vaccination: 14:1 ROI. Historical US elimination efforts (1966-1974): benefit-cost ratio of 10.3:1 with net benefits exceeding USD 1.1 billion (1972 dollars, or USD 8.0 billion in 2023 dollars). 2-dose MMR programs show direct benefit/cost ratio of 14.2 with net savings of $5.3 billion, and 26.0 from societal perspectives with net savings of $11.6 billion. Additional sources: https://www.mdpi.com/2076-393X/12/11/1210 | https://www.tandfonline.com/doi/full/10.1080/14760584.2024.2367451

.

63.

Gosse, M. E. Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold. Sustainability Impact Metrics https://ecocostsvalue.com/EVR/img/references%20others/Gosse%202008%20QALY%20threshold%20financial.pdf (2008).

64.

World Health Organization. Mental health global burden. World Health Organization https://www.who.int/news/item/28-09-2001-the-world-health-report-2001-mental-disorders-affect-one-in-four-people (2022)

One in four people in the world will be affected by mental or neurological disorders at some point in their lives, representing [approximately] 30% of the global burden of disease. Additional sources: https://www.who.int/news/item/28-09-2001-the-world-health-report-2001-mental-disorders-affect-one-in-four-people

.

65.

Stockholm International Peace Research Institute. Trends in world military expenditure, 2023. (2024).

66.

Calculated from Orphanet Journal of Rare Diseases (2024). Diseases getting first effective treatment each year. Calculated from Orphanet Journal of Rare Diseases (2024) https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03398-1 (2024)

Under the current system, approximately 10-15 diseases per year receive their FIRST effective treatment. Calculation: 5% of 7,000 rare diseases ( 350) have FDA-approved treatment, accumulated over 40 years of the Orphan Drug Act =  9 rare diseases/year. Adding  5-10 non-rare diseases that get first treatments yields  10-20 total. FDA approves  50 drugs/year, but many are for diseases that already have treatments (me-too drugs, second-line therapies). Only  15 represent truly FIRST treatments for previously untreatable conditions.

67.

NIH. NIH budget (FY 2025). NIH https://www.nih.gov/about-nih/organization/budget (2024)

The budget total of $47.7 billion also includes $1.412 billion derived from PHS Evaluation financing... Additional sources: https://www.nih.gov/about-nih/organization/budget | https://officeofbudget.od.nih.gov/

.

68.

Bentley et al. NIH spending on clinical trials:  3.3%. Bentley et al. https://pmc.ncbi.nlm.nih.gov/articles/PMC10349341/ (2023)

NIH spent $8.1 billion on clinical trials for approved drugs (2010-2019), representing 3.3% of relevant NIH spending. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10349341/ | https://catalyst.harvard.edu/news/article/nih-spent-8-1b-for-phased-clinical-trials-of-drugs-approved-2010-19-10-of-reported-industry-spending/

.

69.

PMC. Standard medical research ROI ($20k-$100k/QALY). PMC: Cost-effectiveness Thresholds Used by Study Authors https://pmc.ncbi.nlm.nih.gov/articles/PMC10114019/ (1990)

Typical cost-effectiveness thresholds for medical interventions in rich countries range from $50,000 to $150,000 per QALY. The Institute for Clinical and Economic Review (ICER) uses a $100,000-$150,000/QALY threshold for value-based pricing. Between 1990-2021, authors increasingly cited $100,000 (47% by 2020-21) or $150,000 (24% by 2020-21) per QALY as benchmarks for cost-effectiveness. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10114019/ | https://icer.org/our-approach/methods-process/cost-effectiveness-the-qaly-and-the-evlyg/

.

70.

Manhattan Institute. RECOVERY trial 82× cost reduction. Manhattan Institute: Slow Costly Trials https://manhattan.institute/article/slow-costly-clinical-trials-drag-down-biomedical-breakthroughs

RECOVERY trial:  $500 per patient ($20M for 48,000 patients = $417/patient) Typical clinical trial:  $41,000 median per-patient cost Cost reduction:  80-82× cheaper ($41,000 ÷ $500 ≈ 82×) Efficiency: $50 per patient per answer (10 therapeutics tested, 4 effective) Dexamethasone estimated to save >630,000 lives Additional sources: https://manhattan.institute/article/slow-costly-clinical-trials-drag-down-biomedical-breakthroughs | https://pmc.ncbi.nlm.nih.gov/articles/PMC9293394/

.

71.

Trials. Patient willingness to participate in clinical trials. Trials: Patients’ Willingness Survey https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-1105-3

Recent surveys: 49-51% willingness (2020-2022) - dramatic drop from 85% (2019) during COVID-19 pandemic Cancer patients when approached: 88% consented to trials (Royal Marsden Hospital) Study type variation: 44.8% willing for drug trial, 76.2% for diagnostic study Top motivation: "Learning more about my health/medical condition" (67.4%) Top barrier: "Worry about experiencing side effects" (52.6%) Additional sources: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-1105-3 | https://www.appliedclinicaltrialsonline.com/view/industry-forced-to-rethink-patient-participation-in-trials | https://pmc.ncbi.nlm.nih.gov/articles/PMC7183682/

.

72.

Tufts CSDD. Cost of drug development.

Various estimates suggest $1.0 - $2.5 billion to bring a new drug from discovery through FDA approval, spread across  10 years. Tufts Center for the Study of Drug Development often cited for $1.0 - $2.6 billion/drug. Industry reports (IQVIA, Deloitte) also highlight $2+ billion figures.

73.

Value in Health. Average lifetime revenue per successful drug. Value in Health: Sales Revenues for New Therapeutic Agents https://www.sciencedirect.com/science/article/pii/S1098301524027542

Study of 361 FDA-approved drugs from 1995-2014 (median follow-up 13.2 years): Mean lifetime revenue: $15.2 billion per drug Median lifetime revenue: $6.7 billion per drug Revenue after 5 years: $3.2 billion (mean) Revenue after 10 years: $9.5 billion (mean) Revenue after 15 years: $19.2 billion (mean) Distribution highly skewed: top 25 drugs (7%) accounted for 38% of total revenue ($2.1T of $5.5T) Additional sources: https://www.sciencedirect.com/science/article/pii/S1098301524027542

.

74.

Lichtenberg, F. R. How many life-years have new drugs saved? A three-way fixed-effects analysis of 66 diseases in 27 countries, 2000-2013. International Health 11, 403–416 (2019)

Using 3-way fixed-effects methodology (disease-country-year) across 66 diseases in 22 countries, this study estimates that drugs launched after 1981 saved 148.7 million life-years in 2013 alone. The regression coefficients for drug launches 0-11 years prior (beta=-0.031, SE=0.008) and 12+ years prior (beta=-0.057, SE=0.013) on years of life lost are highly significant (p<0.0001). Confidence interval for life-years saved: 79.4M-239.8M (95 percent CI) based on propagated standard errors from Table 2.

75.

Deloitte. Pharmaceutical r&d return on investment (ROI). Deloitte: Measuring Pharmaceutical Innovation 2025 https://www.deloitte.com/ch/en/Industries/life-sciences-health-care/research/measuring-return-from-pharmaceutical-innovation.html (2025)

Deloitte’s annual study of top 20 pharma companies by R&D spend (2010-2024): 2024 ROI: 5.9% (second year of growth after decade of decline) 2023 ROI:  4.3% (estimated from trend) 2022 ROI: 1.2% (historic low since study began, 13-year low) 2021 ROI: 6.8% (record high, inflated by COVID-19 vaccines/treatments) Long-term trend: Declining for over a decade before 2023 recovery Average R&D cost per asset: $2.3B (2022), $2.23B (2024) These returns (1.2-5.9% range) fall far below typical corporate ROI targets (15-20%) Additional sources: https://www.deloitte.com/ch/en/Industries/life-sciences-health-care/research/measuring-return-from-pharmaceutical-innovation.html | https://www.prnewswire.com/news-releases/deloittes-13th-annual-pharmaceutical-innovation-report-pharma-rd-return-on-investment-falls-in-post-pandemic-market-301738807.html | https://hitconsultant.net/2023/02/16/pharma-rd-roi-falls-to-lowest-level-in-13-years/

.

76.

Nature Reviews Drug Discovery. Drug trial success rate from phase i to approval. Nature Reviews Drug Discovery: Clinical Success Rates https://www.nature.com/articles/nrd.2016.136 (2016)

Overall Phase I to approval: 10-12.8% (conventional wisdom  10%, studies show 12.8%) Recent decline: Average LOA now 6.7% for Phase I (2014-2023 data) Leading pharma companies: 14.3% average LOA (range 8-23%) Varies by therapeutic area: Oncology 3.4%, CNS/cardiovascular lowest at Phase III Phase-specific success: Phase I 47-54%, Phase II 28-34%, Phase III 55-70% Note: 12% figure accurate for historical average. Recent data shows decline to 6.7%, with Phase II as primary attrition point (28% success) Additional sources: https://www.nature.com/articles/nrd.2016.136 | https://pmc.ncbi.nlm.nih.gov/articles/PMC6409418/ | https://academic.oup.com/biostatistics/article/20/2/273/4817524

.

77.

SofproMed. Phase 3 cost per trial range. SofproMed https://www.sofpromed.com/how-much-does-a-clinical-trial-cost

Phase 3 clinical trials cost between $20 million and $282 million per trial, with significant variation by therapeutic area and trial complexity. Additional sources: https://www.sofpromed.com/how-much-does-a-clinical-trial-cost | https://www.cbo.gov/publication/57126

.

78.

Ramsberg, J. & Platt, R. Pragmatic trial cost per patient (median $97). Learning Health Systems https://pmc.ncbi.nlm.nih.gov/articles/PMC6508852/ (2018)

Meta-analysis of 108 embedded pragmatic clinical trials (2006-2016). The median cost per patient was $97 (IQR $19–$478), based on 2015 dollars. 25% of trials cost <$19/patient; 10 trials exceeded $1,000/patient. U.S. studies median $187 vs non-U.S. median $27. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6508852/

.

79.

WHO. Polio vaccination ROI. WHO https://www.who.int/news-room/feature-stories/detail/sustaining-polio-investments-offers-a-high-return (2019)

For every dollar spent, the return on investment is nearly US$ 39." Total investment cost of US$ 7.5 billion generates projected economic and social benefits of US$ 289.2 billion from sustaining polio assets and integrating them into expanded immunization, surveillance and emergency response programmes across 8 priority countries (Afghanistan, Iraq, Libya, Pakistan, Somalia, Sudan, Syria, Yemen). Additional sources: https://www.who.int/news-room/feature-stories/detail/sustaining-polio-investments-offers-a-high-return

.

80.

ICRC. International campaign to ban landmines (ICBL) - ottawa treaty (1997). ICRC https://www.icrc.org/en/doc/resources/documents/article/other/57jpjn.htm (1997)

ICBL: Founded 1992 by 6 NGOs (Handicap International, Human Rights Watch, Medico International, Mines Advisory Group, Physicians for Human Rights, Vietnam Veterans of America Foundation) Started with ONE staff member: Jody Williams as founding coordinator Grew to 1,000+ organizations in 60 countries by 1997 Ottawa Process: 14 months (October 1996 - December 1997) Convention signed by 122 states on December 3, 1997; entered into force March 1, 1999 Achievement: Nobel Peace Prize 1997 (shared by ICBL and Jody Williams) Government funding context: Canada established $100M CAD Canadian Landmine Fund over 10 years (1997); International donors provided $169M in 1997 for mine action (up from $100M in 1996) Additional sources: https://www.icrc.org/en/doc/resources/documents/article/other/57jpjn.htm | https://en.wikipedia.org/wiki/International_Campaign_to_Ban_Landmines | https://www.nobelprize.org/prizes/peace/1997/summary/ | https://un.org/press/en/1999/19990520.MINES.BRF.html | https://www.the-monitor.org/en-gb/reports/2003/landmine-monitor-2003/mine-action-funding.aspx

.

81.

OpenSecrets. Revolving door: Former members of congress. (2024)

388 former members of Congress are registered as lobbyists. Nearly 5,400 former congressional staffers have left Capitol Hill to become federal lobbyists in the past 10 years. Additional sources: https://www.opensecrets.org/revolving-door

.

82.

Kinch, M. S. & Griesenauer, R. H. Lost medicines: A longer view of the pharmaceutical industry with the potential to reinvigorate discovery. Drug Discovery Today 24, 875–880 (2019)

Research identified 1,600+ medicines available in 1962. The 1950s represented industry high-water mark with >30 new products in five of ten years; this rate would not be replicated until late 1990s. More than half (880) of these medicines were lost following implementation of Kefauver-Harris Amendment. The peak of 1962 would not be seen again until early 21st century. By 2016 number of organizations actively involved in R&D at level not seen since 1914.

83.

Baily, M. N. Pre-1962 drug development costs (baily 1972). Baily (1972) https://samizdathealth.org/wp-content/uploads/2020/12/hlthaff.1.2.6.pdf (1972)

Pre-1962: Average cost per new chemical entity (NCE) was $6.5 million (1980 dollars) Inflation-adjusted to 2024 dollars: $6.5M (1980) ≈ $22.5M (2024), using CPI multiplier of 3.46× Real cost increase (inflation-adjusted): $22.5M (pre-1962) → $2,600M (2024) = 116× increase Note: This represents the most comprehensive academic estimate of pre-1962 drug development costs based on empirical industry data Additional sources: https://samizdathealth.org/wp-content/uploads/2020/12/hlthaff.1.2.6.pdf

.

84.

Think by Numbers. Pre-1962 physician-led clinical trials. Think by Numbers: How Many Lives Does FDA Save? https://thinkbynumbers.org/health/how-many-net-lives-does-the-fda-save/ (1966)

Pre-1962: Physicians could report real-world evidence directly 1962 Drug Amendments replaced "premarket notification" with "premarket approval", requiring extensive efficacy testing Impact: New regulatory clampdown reduced new treatment production by 70%; lifespan growth declined from  4 years/decade to  2 years/decade Drug Efficacy Study Implementation (DESI): NAS/NRC evaluated 3,400+ drugs approved 1938-1962 for safety only; reviewed >3,000 products, >16,000 therapeutic claims FDA has had authority to accept real-world evidence since 1962, clarified by 21st Century Cures Act (2016) Note: Specific "144,000 physicians" figure not verified in sources Additional sources: https://thinkbynumbers.org/health/how-many-net-lives-does-the-fda-save/ | https://www.fda.gov/drugs/enforcement-activities-fda/drug-efficacy-study-implementation-desi | http://www.nasonline.org/about-nas/history/archives/collections/des-1966-1969-1.html

.

85.

GAO. 95% of diseases have 0 FDA-approved treatments. GAO https://www.gao.gov/products/gao-25-106774 (2025)

95% of diseases have no treatment Additional sources: https://www.gao.gov/products/gao-25-106774 | https://globalgenes.org/rare-disease-facts/

.

86.

Oren Cass, Manhattan Institute. RECOVERY trial cost per patient. Oren Cass https://manhattan.institute/article/slow-costly-clinical-trials-drag-down-biomedical-breakthroughs (2023)

The RECOVERY trial, for example, cost only about $500 per patient... By contrast, the median per-patient cost of a pivotal trial for a new therapeutic is around $41,000. Additional sources: https://manhattan.institute/article/slow-costly-clinical-trials-drag-down-biomedical-breakthroughs

.

87.

NHS England; Águas et al. RECOVERY trial global lives saved ( 1 million). NHS England: 1 Million Lives Saved https://www.england.nhs.uk/2021/03/covid-treatment-developed-in-the-nhs-saves-a-million-lives/ (2021)

Dexamethasone saved  1 million lives worldwide (NHS England estimate, March 2021, 9 months after discovery). UK alone: 22,000 lives saved. Methodology: Águas et al. Nature Communications 2021 estimated 650,000 lives (range: 240,000-1,400,000) for July-December 2020 alone, based on RECOVERY trial mortality reductions (36% for ventilated, 18% for oxygen-only patients) applied to global COVID hospitalizations. June 2020 announcement: Dexamethasone reduced deaths by up to 1/3 (ventilated patients), 1/5 (oxygen patients). Impact immediate: Adopted into standard care globally within hours of announcement. Additional sources: https://www.england.nhs.uk/2021/03/covid-treatment-developed-in-the-nhs-saves-a-million-lives/ | https://www.nature.com/articles/s41467-021-21134-2 | https://pharmaceutical-journal.com/article/news/steroid-has-saved-the-lives-of-one-million-covid-19-patients-worldwide-figures-show | https://www.recoverytrial.net/news/recovery-trial-celebrates-two-year-anniversary-of-life-saving-dexamethasone-result

.

88.

National September 11 Memorial & Museum. September 11 attack facts. (2024)

2,977 people were killed in the September 11, 2001 attacks: 2,753 at the World Trade Center, 184 at the Pentagon, and 40 passengers and crew on United Flight 93 in Shanksville, Pennsylvania.

89.

World Bank. World bank singapore economic data. World Bank https://data.worldbank.org/country/singapore (2024)

Singapore GDP per capita (2023): $82,000 - among highest in the world Government spending: 15% of GDP (vs US 38%) Life expectancy: 84.1 years (vs US 77.5 years) Singapore demonstrates that low government spending can coexist with excellent outcomes Additional sources: https://data.worldbank.org/country/singapore

.

90.

International Monetary Fund. IMF singapore government spending data. (2024)

Singapore government spending is approximately 15% of GDP This is 23 percentage points lower than the United States (38%) Despite lower spending, Singapore achieves excellent outcomes: - Life expectancy: 84.1 years (vs US 77.5) - Low crime, world-class infrastructure, AAA credit rating Additional sources: https://www.imf.org/en/Countries/SGP

.

91.

World Health Organization. WHO life expectancy data by country. (2024)

Life expectancy at birth varies significantly among developed nations: Switzerland: 84.0 years (2023) Singapore: 84.1 years (2023) Japan: 84.3 years (2023) United States: 77.5 years (2023) - 6.5 years below Switzerland, Singapore Global average:  73 years Note: US spends more per capita on healthcare than any other nation, yet achieves lower life expectancy Additional sources: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-life-expectancy-and-healthy-life-expectancy

.

92.

CSIS. Smallpox eradication ROI. CSIS https://www.csis.org/analysis/smallpox-eradication-model-global-cooperation.

93.

PMC. Contribution of smoking reduction to life expectancy gains. PMC: Benefits Smoking Cessation Longevity https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1447499/ (2012)

Population-level: Up to 14% (9% men, 14% women) of total life expectancy gain since 1960 due to tobacco control efforts Individual cessation benefits: Quitting at age 35 adds 6.9-8.5 years (men), 6.1-7.7 years (women) vs continuing smokers By cessation age: Age 25-34 = 10 years gained; age 35-44 = 9 years; age 45-54 = 6 years; age 65 = 2.0 years (men), 3.7 years (women) Cessation before age 40: Reduces death risk by  90% Long-term cessation: 10+ years yields survival comparable to never smokers, averts  10 years of life lost Recent cessation: <3 years averts  5 years of life lost Additional sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1447499/ | https://www.cdc.gov/pcd/issues/2012/11_0295.htm | https://www.ajpmonline.org/article/S0749-3797(24)00217-4/fulltext | https://www.nejm.org/doi/full/10.1056/NEJMsa1211128

.

94.

ICER. Value per QALY (standard economic value). ICER https://icer.org/wp-content/uploads/2024/02/Reference-Case-4.3.25.pdf (2024)

Standard economic value per QALY: $100,000–$150,000. This is the US and global standard willingness-to-pay threshold for interventions that add costs. Dominant interventions (those that save money while improving health) are favorable regardless of this threshold. Additional sources: https://icer.org/wp-content/uploads/2024/02/Reference-Case-4.3.25.pdf

.

95.

GAO. Annual cost of u.s. Sugar subsidies. GAO: Sugar Program https://www.gao.gov/products/gao-24-106144

Consumer costs: $2.5-3.5 billion per year (GAO estimate) Net economic cost:  $1 billion per year 2022: US consumers paid 2X world price for sugar Program costs $3-4 billion/year but no federal budget impact (costs passed directly to consumers via higher prices) Employment impact: 10,000-20,000 manufacturing jobs lost annually in sugar-reliant industries (confectionery, etc.) Multiple studies confirm: Sweetener Users Association ($2.9-3.5B), AEI ($2.4B consumer cost), Beghin & Elobeid ($2.9-3.5B consumer surplus) Additional sources: https://www.gao.gov/products/gao-24-106144 | https://www.heritage.org/agriculture/report/the-us-sugar-program-bad-consumers-bad-agriculture-and-bad-america | https://www.aei.org/articles/the-u-s-spends-4-billion-a-year-subsidizing-stalinist-style-domestic-sugar-production/

.

96.

World Bank. Swiss military budget as percentage of GDP. World Bank: Military Expenditure https://data.worldbank.org/indicator/MS.MIL.XPND.GD.ZS?locations=CH

2023: 0.70272% of GDP (World Bank) 2024: CHF 5.95 billion official military spending When including militia system costs:  1% GDP (CHF 8.75B) Comparison: Near bottom in Europe; only Ireland, Malta, Moldova spend less (excluding microstates with no armies) Additional sources: https://data.worldbank.org/indicator/MS.MIL.XPND.GD.ZS?locations=CH | https://www.avenir-suisse.ch/en/blog-defence-spending-switzerland-is-in-better-shape-than-it-seems/ | https://tradingeconomics.com/switzerland/military-expenditure-percent-of-gdp-wb-data.html

.

97.

World Bank. Switzerland vs. US GDP per capita comparison. World Bank: Switzerland GDP Per Capita https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=CH

2024 GDP per capita (PPP-adjusted): Switzerland $93,819 vs United States $75,492 Switzerland’s GDP per capita 24% higher than US when adjusted for purchasing power parity Nominal 2024: Switzerland $103,670 vs US $85,810 Additional sources: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=CH | https://tradingeconomics.com/switzerland/gdp-per-capita-ppp | https://www.theglobaleconomy.com/USA/gdp_per_capita_ppp/

.

98.

OECD. OECD government spending as percentage of GDP. (2024)

OECD government spending data shows significant variation among developed nations: United States: 38.0% of GDP (2023) Switzerland: 35.0% of GDP - 3 percentage points lower than US Singapore: 15.0% of GDP - 23 percentage points lower than US (per IMF data) OECD average: approximately 40% of GDP Additional sources: https://data.oecd.org/gga/general-government-spending.htm

.

99.

OECD. OECD median household income comparison. (2024)

Median household disposable income varies significantly across OECD nations: United States: $77,500 (2023) Switzerland: $55,000 PPP-adjusted (lower nominal but comparable purchasing power) Singapore: $75,000 PPP-adjusted Additional sources: https://data.oecd.org/hha/household-disposable-income.htm

.

100.

Cato Institute. Chance of dying from terrorism statistic. Cato Institute: Terrorism and Immigration Risk Analysis https://www.cato.org/policy-analysis/terrorism-immigration-risk-analysis

Chance of American dying in foreign-born terrorist attack: 1 in 3.6 million per year (1975-2015) Including 9/11 deaths; annual murder rate is 253x higher than terrorism death rate More likely to die from lightning strike than foreign terrorism Note: Comprehensive 41-year study shows terrorism risk is extremely low compared to everyday dangers Additional sources: https://www.cato.org/policy-analysis/terrorism-immigration-risk-analysis | https://www.nbcnews.com/news/us-news/you-re-more-likely-die-choking-be-killed-foreign-terrorists-n715141

.

101.

Wikipedia. Thalidomide scandal: Worldwide cases and mortality. Wikipedia https://en.wikipedia.org/wiki/Thalidomide_scandal

The total number of embryos affected by the use of thalidomide during pregnancy is estimated at 10,000, of whom about 40% died around the time of birth. More than 10,000 children in 46 countries were born with deformities such as phocomelia. Additional sources: https://en.wikipedia.org/wiki/Thalidomide_scandal

.

102.

PLOS One. Health and quality of life of thalidomide survivors as they age. PLOS One https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210222 (2019)

Study of thalidomide survivors documenting ongoing disability impacts, quality of life, and long-term health outcomes. Survivors (now in their 60s) continue to experience significant disability from limb deformities, organ damage, and other effects. Additional sources: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210222

.

103.

US Census Bureau. Historical world population estimates. US Census Bureau https://www.census.gov/data/tables/time-series/demo/international-programs/historical-est-worldpop.html

US Census Bureau historical estimates of world population by country and region (1950-2050). US population in 1960:  180 million of  3 billion worldwide (6%). Additional sources: https://www.census.gov/data/tables/time-series/demo/international-programs/historical-est-worldpop.html

.

104.

FDA Study via NCBI. Trial costs, FDA study. FDA Study via NCBI https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248200/

Overall, the 138 clinical trials had an estimated median (IQR) cost of $19.0 million ($12.2 million-$33.1 million)... The clinical trials cost a median (IQR) of $41,117 ($31,802-$82,362) per patient. Additional sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248200/

.

105.

GBD 2019 Diseases and Injuries Collaborators. Global burden of disease study 2019: Disability weights. The Lancet 396, 1204–1222 (2020)

Disability weights for 235 health states used in Global Burden of Disease calculations. Weights range from 0 (perfect health) to 1 (death equivalent). Chronic conditions like diabetes (0.05-0.35), COPD (0.04-0.41), depression (0.15-0.66), and cardiovascular disease (0.04-0.57) show substantial variation by severity. Treatment typically reduces disability weights by 50-80 percent for manageable chronic conditions.

106.

WHO. Annual global economic burden of alzheimer’s and other dementias. WHO: Dementia Fact Sheet https://www.who.int/news-room/fact-sheets/detail/dementia (2019)

Global cost: $1.3 trillion (2019 WHO-commissioned study) 50% from informal caregivers (family/friends,  5 hrs/day) 74% of costs in high-income countries despite 61% of patients in LMICs $818B (2010) → $1T (2018) → $1.3T (2019) - rapid growth Note: Costs increased 35% from 2010-2015 alone. Informal care represents massive hidden economic burden Additional sources: https://www.who.int/news-room/fact-sheets/detail/dementia | https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12901

.

107.

JAMA Oncology. Annual global economic burden of cancer. JAMA Oncology: Global Cost 2020-2050 https://jamanetwork.com/journals/jamaoncology/fullarticle/2801798 (2020)

2020-2050 projection: $25.2 trillion total ($840B/year average) 2010 annual cost: $1.16 trillion (direct costs only) Recent estimate:  $3 trillion/year (all costs included) Top 5 cancers: lung (15.4%), colon/rectum (10.9%), breast (7.7%), liver (6.5%), leukemia (6.3%) Note: China/US account for 45% of global burden; 75% of deaths in LMICs but only 50.0% of economic cost Additional sources: https://jamanetwork.com/journals/jamaoncology/fullarticle/2801798 | https://www.nature.com/articles/d41586-023-00634-9

.

108.

CDC. U.s. Chronic disease healthcare spending. CDC https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html

Chronic diseases account for  90% of U.S. healthcare spending ( $3.7T/year). Additional sources: https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html

.

109.

Diabetes Care. Annual global economic burden of diabetes. Diabetes Care: Global Economic Burden https://diabetesjournals.org/care/article/41/5/963/36522/Global-Economic-Burden-of-Diabetes-in-Adults

2015: $1.3 trillion (1.8% of global GDP) 2030 projections: $2.1T-2.5T depending on scenario IDF health expenditure: $760B (2019) → $845B (2045 projected) 2/3 direct medical costs ($857B), 1/3 indirect costs (lost productivity) Note: Costs growing rapidly; expected to exceed $2T by 2030 Additional sources: https://diabetesjournals.org/care/article/41/5/963/36522/Global-Economic-Burden-of-Diabetes-in-Adults | https://doi.org/10.1016/S2213-8587(17)30097-9

.

110.

CBO. The 2024 Long-Term Budget Outlook. https://www.cbo.gov/publication/60039 (2024).

111.

World Bank, Bureau of Economic Analysis. US GDP 2024 ($28.78 trillion). World Bank https://data.worldbank.org/indicator/NY.GDP.MKTP.CD?locations=US (2024)

US GDP reached $28.78 trillion in 2024, representing approximately 26% of global GDP. Additional sources: https://data.worldbank.org/indicator/NY.GDP.MKTP.CD?locations=US | https://www.bea.gov/news/2024/gross-domestic-product-fourth-quarter-and-year-2024-advance-estimate

.

112.

Environmental Working Group. US farm subsidy database and analysis. Environmental Working Group https://farm.ewg.org/ (2024)

US agricultural subsidies total approximately $30 billion annually, but create much larger economic distortions. Top 10% of farms receive 78% of subsidies, benefits concentrated in commodity crops (corn, soy, wheat, cotton), environmental damage from monoculture incentivized, and overall deadweight loss estimated at $50-120 billion annually. Additional sources: https://farm.ewg.org/ | https://www.ers.usda.gov/topics/farm-economy/farm-sector-income-finances/government-payments-the-safety-net/

.

113.

Drug Policy Alliance. The drug war by the numbers. (2021)

Since 1971, the war on drugs has cost the United States an estimated $1 trillion in enforcement. The federal drug control budget was $41 billion in 2022. Mass incarceration costs the U.S. at least $182 billion every year, with over $450 billion spent to incarcerate individuals on drug charges in federal prisons.

114.

International Monetary Fund. IMF fossil fuel subsidies data: 2023 update. (2023)

Globally, fossil fuel subsidies were $7 trillion in 2022 or 7.1 percent of GDP. The United States subsidies totaled $649 billion. Underpricing for local air pollution costs and climate damages are the largest contributor, accounting for about 30 percent each.

115.

Papanicolas, Irene et al. Health care spending in the united states and other high-income countries. Papanicolas et al. https://jamanetwork.com/journals/jama/article-abstract/2674671 (2018)

The US spent approximately twice as much as other high-income countries on medical care (mean per capita: $9,892 vs $5,289), with similar utilization but much higher prices. Administrative costs accounted for 8% of US spending vs 1-3% in other countries. US spending on pharmaceuticals was $1,443 per capita vs $749 elsewhere. Despite spending more, US health outcomes are not better. Additional sources: https://jamanetwork.com/journals/jama/article-abstract/2674671

.

116.

Hsieh, C.-T. & Moretti, E. Housing constraints and spatial misallocation. American Economic Journal: Macroeconomics https://www.aeaweb.org/articles?id=10.1257/mac.20170388 (2019)

We quantify the amount of spatial misallocation of labor across US cities and its aggregate costs. Tight land-use restrictions in high-productivity cities like New York, San Francisco, and Boston lowered aggregate US growth by 36% from 1964 to 2009. Local constraints on housing supply have had enormous effects on the national economy. Additional sources: https://www.aeaweb.org/articles?id=10.1257/mac.20170388

.

117.

Yale Budget Lab. The fiscal, economic, and distributional effects of all u.s. tariffs. (2025)

Accounting for all the 2025 US tariffs and retaliation implemented to date, the level of real GDP is persistently -0.6% smaller in the long run, the equivalent of $160 billion 2024$ annually.

118.

Tax Foundation. Tax compliance costs the US economy $546 billion annually. https://taxfoundation.org/data/all/federal/irs-tax-compliance-costs/ (2024)

Americans will spend over 7.9 billion hours complying with IRS tax filing and reporting requirements in 2024. This costs the economy roughly $413 billion in lost productivity. In addition, the IRS estimates that Americans spend roughly $133 billion annually in out-of-pocket costs, bringing the total compliance costs to $546 billion, or nearly 2 percent of GDP.

119.

Cook, C., Cole, G., Asaria, P., Jabbour, R. & Francis, D. P. Annual global economic burden of heart disease. International Journal of Cardiology https://www.internationaljournalofcardiology.com/article/S0167-5273(13)02238-9/abstract (2014)

Heart failure alone: $108 billion/year (2012 global analysis, 197 countries) US CVD: $555B (2016) → projected $1.8T by 2050 LMICs total CVD loss: $3.7T cumulative (2011-2015, 5-year period) CVD is costliest disease category in most developed nations Note: No single $2.1T global figure found; estimates vary widely by scope and year Additional sources: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001258

.

120.

Source: US Life Expectancy FDA Budget 1543-2019 CSV. US life expectancy growth 1880-1960: 3.82 years per decade. (2019)

Pre-1962: 3.82 years/decade Post-1962: 1.54 years/decade Reduction: 60% decline in life expectancy growth rate Additional sources: https://ourworldindata.org/life-expectancy | https://www.mortality.org/ | https://www.cdc.gov/nchs/nvss/mortality_tables.htm

.

121.

Source: US Life Expectancy FDA Budget 1543-2019 CSV. Post-1962 slowdown in life expectancy gains. (2019)

Pre-1962 (1880-1960): 3.82 years/decade Post-1962 (1962-2019): 1.54 years/decade Reduction: 60% decline Temporal correlation: Slowdown occurred immediately after 1962 Kefauver-Harris Amendment Additional sources: https://ourworldindata.org/life-expectancy | https://www.mortality.org/ | https://www.cdc.gov/nchs/nvss/mortality_tables.htm

.

122.

Centers for Disease Control and Prevention. US life expectancy 2023. (2024)

US life expectancy at birth was 77.5 years in 2023 Male life expectancy: 74.8 years Female life expectancy: 80.2 years This is 6-7 years lower than peer developed nations despite higher healthcare spending Additional sources: https://www.cdc.gov/nchs/fastats/life-expectancy.htm

.

123.

US Census Bureau. US median household income 2023. (2024)

US median household income was $77,500 in 2023 Real median household income declined 0.8% from 2022 Gini index: 0.467 (income inequality measure) Additional sources: https://www.census.gov/library/publications/2024/demo/p60-282.html

.

124.

Manuel, D. U.s. Defense spending history: 100 years of military budgets. DaveManuel.com https://www.davemanuel.com/us-defense-spending-history-military-budget-data.php (2025)

US military spending in constant 2024 dollars: 1939 $29B (pre-WW2 baseline), 1940 $37B, 1944 $1,383B, 1945 $1,420B (peak), 1946 $674B, 1947 $176B, 1948 $117B, 2024 $886B. The post-WW2 demobilization cut spending 88% in two years (1945-1947). Current peacetime spending ($886B) is 30x the pre-WW2 baseline and 62% of peak WW2 spending, in inflation-adjusted dollars.

125.

Statista. US military budget as percentage of GDP. Statista https://www.statista.com/statistics/262742/countries-with-the-highest-military-spending/ (2024)

U.S. military spending amounted to 3.5% of GDP in 2024. In 2024, the U.S. spent nearly $1 trillion on its military budget, equal to 3.4% of GDP. Additional sources: https://www.statista.com/statistics/262742/countries-with-the-highest-military-spending/ | https://www.sipri.org/sites/default/files/2025-04/2504_fs_milex_2024.pdf

.

126.

US Census Bureau. Number of registered or eligible voters in the u.s. US Census Bureau https://www.census.gov/newsroom/press-releases/2025/2024-presidential-election-voting-registration-tables.html (2024)

73.6% (or 174 million people) of the citizen voting-age population was registered to vote in 2024 (Census Bureau). More than 211 million citizens were active registered voters (86.6% of citizen voting age population) according to the Election Assistance Commission. Additional sources: https://www.census.gov/newsroom/press-releases/2025/2024-presidential-election-voting-registration-tables.html | https://www.eac.gov/news/2025/06/30/us-election-assistance-commission-releases-2024-election-administration-and-voting

.

127.

U.S. Senate. Treaties. U.S. Senate https://www.senate.gov/about/powers-procedures/treaties.htm

The Constitution provides that the president ’shall have Power, by and with the Advice and Consent of the Senate, to make Treaties, provided two-thirds of the Senators present concur’ (Article II, section 2). Treaties are formal agreements with foreign nations that require two-thirds Senate approval. 67 senators (two-thirds of 100) must vote to ratify a treaty for it to take effect. Additional sources: https://www.senate.gov/about/powers-procedures/treaties.htm

.

128.

Federal Election Commission. Statistical summary of 24-month campaign activity of the 2023-2024 election cycle. (2023)

Presidential candidates raised $2 billion; House and Senate candidates raised $3.8 billion and spent $3.7 billion; PACs raised $15.7 billion and spent $15.5 billion. Total federal campaign spending approximately $20 billion. Additional sources: https://www.fec.gov/updates/statistical-summary-of-24-month-campaign-activity-of-the-2023-2024-election-cycle/

.

129.

OpenSecrets. Federal lobbying hit record $4.4 billion in 2024. (2024)

Total federal lobbying reached record $4.4 billion in 2024. The $150 million increase in lobbying continues an upward trend that began in 2016. Additional sources: https://www.opensecrets.org/news/2025/02/federal-lobbying-set-new-record-in-2024/

.

130.

Columbia/NBER. Odds of a single vote being decisive in a u.s. Presidential election. Columbia/NBER: What Is the Probability Your Vote Will Make a Difference? https://sites.stat.columbia.edu/gelman/research/published/probdecisive2.pdf (2012)

National average: 1 in 60 million chance (2008 election analysis by Gelman, Silver, Edlin) Swing states (NM, VA, NH, CO):  1 in 10 million chance Non-competitive states: 34 states >1 in 100 million odds; 20 states >1 in 1 billion Washington DC: 1 in 490 billion odds Methodology: Probability state is necessary for electoral college win × probability state vote is tied Additional sources: https://sites.stat.columbia.edu/gelman/research/published/probdecisive2.pdf | https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1465-7295.2010.00272.x

.

131.

Hutchinson and Kirk. Valley of death in drug development. (2011)

The overall failure rate of drugs that passed into Phase 1 trials to final approval is 90%. This lack of translation from promising preclinical findings to success in human trials is known as the "valley of death." Estimated 30-50% of promising compounds never proceed to Phase 2/3 trials primarily due to funding barriers rather than scientific failure. The late-stage attrition rate for oncology drugs is as high as 70% in Phase II and 59% in Phase III trials.

132.

DOT. DOT value of statistical life ($13.6M). DOT: VSL Guidance 2024 https://www.transportation.gov/office-policy/transportation-policy/revised-departmental-guidance-on-valuation-of-a-statistical-life-in-economic-analysis (2024)

Current VSL (2024): $13.7 million (updated from $13.6M) Used in cost-benefit analyses for transportation regulations and infrastructure Methodology updated in 2013 guidance, adjusted annually for inflation and real income VSL represents aggregate willingness to pay for safety improvements that reduce fatalities by one Note: DOT has published VSL guidance periodically since 1993. Current $13.7M reflects 2024 inflation/income adjustments Additional sources: https://www.transportation.gov/office-policy/transportation-policy/revised-departmental-guidance-on-valuation-of-a-statistical-life-in-economic-analysis | https://www.transportation.gov/regulations/economic-values-used-in-analysis

.

133.

PLOS ONE. Cost per DALY for vitamin a supplementation. PLOS ONE: Cost-effectiveness of "Golden Mustard" for Treating Vitamin A Deficiency in India (2010) https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012046 (2010)

India: $23-$50 per DALY averted (least costly intervention, $1,000-$6,100 per death averted) Sub-Saharan Africa (2022): $220-$860 per DALY (Burkina Faso: $220, Kenya: $550, Nigeria: $860) WHO estimates for Africa: $40 per DALY for fortification, $255 for supplementation Uganda fortification: $18-$82 per DALY (oil: $18, sugar: $82) Note: Wide variation reflects differences in baseline VAD prevalence, coverage levels, and whether intervention is supplementation or fortification Additional sources: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012046 | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0266495

.

134.

UN News. Clean water & sanitation (LMICs) ROI. UN News https://news.un.org/en/story/2014/11/484032 (2014).

135.

PMC. Cost-effectiveness threshold ($50,000/QALY). PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC5193154/

The $50,000/QALY threshold is widely used in US health economics literature, originating from dialysis cost benchmarks in the 1980s. In US cost-utility analyses, 77.5% of authors use either $50,000 or $100,000 per QALY as reference points. Most successful health programs cost $3,000-10,000 per QALY. WHO-CHOICE uses GDP per capita multiples (1× GDP/capita = "very cost-effective", 3× GDP/capita = "cost-effective"), which for the US ( $70,000 GDP/capita) translates to $70,000-$210,000/QALY thresholds. Additional sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC5193154/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9278384/

.

136.

Integrated Benefits Institute. Chronic illness workforce productivity loss. Integrated Benefits Institute 2024 https://www.ibiweb.org/resources/chronic-conditions-in-the-us-workforce-prevalence-trends-and-productivity-impacts (2024)

78.4% of U.S. employees have at least one chronic condition (7% increase since 2021) 58% of employees report physical chronic health conditions 28% of all employees experience productivity loss due to chronic conditions Average productivity loss: $4,798 per employee per year Employees with 3+ chronic conditions miss 7.8 days annually vs 2.2 days for those without Note: 28% productivity loss translates to roughly 11 hours per week (28% of 40-hour workweek) Additional sources: https://www.ibiweb.org/resources/chronic-conditions-in-the-us-workforce-prevalence-trends-and-productivity-impacts | https://www.onemedical.com/mediacenter/study-finds-more-than-half-of-employees-are-living-with-chronic-conditions-including-1-in-3-gen-z-and-millennial-employees/ | https://debeaumont.org/news/2025/poll-the-toll-of-chronic-health-conditions-on-employees-and-workplaces/

.

137.

Value captured by 1% treaty of $27+ billion annually.

A 1% treaty redirects 1% of global military spending ($2.7T × 1% = $27.2B) to pragmatic clinical trials, with 10% of this flow (2.7B annually) distributed to VICTORY Incentive Alignment Bondholders as returns.

138.

Sinn, M. P. Incentive Alignment Bonds: Making Public Goods Financially and Politically Profitable. https://iab.warondisease.org (2025) doi:10.5281/zenodo.18203221

Government spending is optimized for lobbying intensity, not net societal value. Programs with 100:1 benefit-cost ratios get billions while programs with negative returns get hundreds of billions. Incentive Alignment Bonds flip this by creating a capital pool that rewards politicians (via campaign support and post-office opportunities) for funding high-NSV programs over low-NSV alternatives. The result: public good becomes private profit for both investors and elected officials.

139.

Sinn, M. P. Wishocracy: Solving the Democratic Principal-Agent Problem Through Pairwise Preference Aggregation. https://wishocracy.warondisease.org (2025) doi:10.5281/zenodo.18205881

Representative democracy suffers from an inescapable principal-agent problem where elected officials’ incentives diverge from citizen welfare. Wishocracy introduces RAPPA (Randomized Aggregated Pairwise Preference Allocation), which aggregates citizen preferences through cognitively tractable pairwise comparisons and creates accountability via Citizen Alignment Scores that channel electoral resources toward politicians who actually represent what citizens want.

140.

Sinn, M. P. Optimocracy: Causal Inference on Cross-Jurisdictional Policy Data to Maximize Median Health and Wealth. https://optimocracy.warondisease.org (2025) doi:10.5281/zenodo.18356213

Thousands of jurisdictions have made different policy and budget choices over decades, creating a natural experiment. Optimocracy applies causal inference to this cross-jurisdictional time-series data to identify which policies predict above-average median income and healthy life years. It then publishes evidence-based recommendations for every major vote, tracks politician alignment, and funds aligned candidates via SuperPAC, making suboptimal policy politically expensive while preserving democratic structures.

141.

Sinn, M. P. The Optimal Policy Generator: A Causal Inference Protocol for Maximizing Median Health and Wealth Through Public Policy. https://opg.warondisease.org (2025) doi:10.5281/zenodo.18603834

The Optimal Policy Generator (OPG) produces systematic public policy recommendations for jurisdictions at any level (country, state, city), generating prioritized enact/replace/repeal/maintain recommendations to maximize real after-tax median income growth and median healthy life years, based on quasi-experimental evidence from centuries of policy variation data.

142.

Sinn, M. P. The Optimal Budget Generator: A Causal Inference Protocol for Maximizing Median Health and Wealth Through Public Goods Funding. https://obg.warondisease.org (2025) doi:10.5281/zenodo.18356209

The Optimal Budget Generator (OBG) uses causal inference, diminishing returns modeling, and cost-effectiveness evidence to determine optimal public goods funding levels that maximize two welfare metrics: real after-tax median income growth and median healthy life years. For each spending category, OBG estimates an Optimal Spending Level (OSL) and produces a gap analysis showing where current government budgets are over- or underfunded relative to evidence-based benchmarks. The Budget Impact Score (BIS) measures confidence in each recommendation based on the quality of causal evidence.

143.

Sinn, M. P. Ubiquitous Pragmatic Trial Impact Analysis: How to Prevent a Year of Death and Suffering for 84 Cents. https://dfda-impact.warondisease.org (2025) doi:10.5281/zenodo.18243914

Only 15 diseases/year get their first treatment each year. With 6.65 thousand diseases lacking effective treatments, the backlog would take 443 years to clear. Integrating pragmatic trials into standard healthcare increases trial capacity 12.3x, cutting that timeline from 443 years to 36 years. The average untreated disease gets a treatment 212 years earlier, saving 10.7 billion deaths at $0.842 per year of healthy life saved.

144.

Sinn, M. P. The Invisible Graveyard: Quantifying the Mortality Cost of FDA Efficacy Lag. https://invisible-graveyard.warondisease.org (2025) doi:10.5281/zenodo.18356231

After proving a drug is safe, the FDA requires 8.2 years to prove it works before patients can access it. We estimate this delay cost 102 million deaths among people waiting for approved drugs (1962-2024). The human cost in death and disability of blocking good drugs is 3.07k higher than the cost of approving bad ones.

145.

Sinn, M. P. The Price of Political Change: A Cost-Benefit Framework for Policy Incentivization. https://cost-of-change.warondisease.org (2025) doi:10.5281/zenodo.18356215

What’s the maximum cost to achieve any policy change through legal democratic channels? $25B for the US, $200B globally. For high-value reforms like military-to-health reallocation, this yields ROI exceeding 400,000:1.

146.

Sinn, M. P. United States Efficiency Audit. https://us-efficiency-audit.warondisease.org (2025) doi:10.5281/zenodo.18447476

Systems audit estimating an annual U.S. efficiency gap of $4.9T, with $2.45T recoverable at OECD-median performance across direct spending waste, compliance burden, policy-induced GDP loss, and system inefficiency.

147.

Sinn, M. P. The Continuous Evidence Generation Protocol: Two-Stage Validation (RWE → Pragmatic Trials). https://dfda-spec.warondisease.org (2025) doi:10.5281/zenodo.18203375

We present the Predictor Impact Score (PIS), a novel composite metric operationalizing Bradford Hill causality criteria for automated signal detection from aggregated N-of-1 observational studies. Combined with pragmatic trial confirmation (based on evidence from 108+ embedded trials), this two-stage framework would generate validated outcome labels at 44.1x lower cost than traditional Phase III trials. This enables continuous, population-scale pharmacovigilance and precision dosing recommendations.

148.

Olson, M. The Logic of Collective Action: Public Goods and the Theory of Groups. (Harvard University Press, Cambridge, MA, 1965).

149.

Kremer, M., Levin, J. & Snyder, C. M. Advance market commitments: Insights from theory and experience. AEA Papers and Proceedings 110, 269–273 (2020)

Reviews the $1.5 billion pilot Advance Market Commitment for pneumococcal vaccine. Three vaccines developed, 150 million children immunized, estimated 700,000 lives saved. Discusses AMC design for well-defined products versus systemic reform.

150.

Sinn, M. P. The 1% Treaty: Harnessing Greed to Eradicate Disease. https://impact.warondisease.org (2025) doi:10.5281/zenodo.18161560

6.65 thousand diseases have zero FDA-approved treatments; at current trial capacity, exploring them takes  443 years. Redirecting 1% of military spending scales capacity 12.3x, cutting the timeline to  36 years and preventing 10.7 billion deaths. At $0.00177/DALY, 50.3kx more cost-effective than the best existing interventions. Incentive Alignment Bonds make adoption politically viable.

151.

Tabarrok, A. The private provision of public goods via dominant assurance contracts. Public Choice 96, 345–362 (1998).

Copyright

© 2025 Mike P. Sinn